

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
4 September 2003 (04.09.2003)

PCT

(10) International Publication Number  
**WO 03/072024 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K**
- (74) Agent: **FRASER, Janis, K.**; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110 (US).
- (21) International Application Number: PCT/US03/04665
- (22) International Filing Date: 13 February 2003 (13.02.2003)
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/356,718 13 February 2002 (13.02.2002) US
- (71) Applicants (*for all designated States except US*): **BETH ISRAEL DEACONESS MEDICAL CENTER, INC.** [US/US]; One Deaconess Road, Boston, MA 02115 (US). **UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION** [US/US]; 200 Gardener Steel Conference Center, Pittsburgh, PA 15260 (US).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **OTTERBEIN, Leo, E.** [US/US]; 910 Normandy Drive, New Kensington, PA 15068 (US). **CHOI, Augustine, M., K.** [US/US]; 43 Long Meadow Dr, Pittsburgh, PA 15238 (US). **BACH, Fritz, H.** [US/US]; 8 Blossom Lane, Manchester-by-the-Sea, MA 01944 (US). **ZUCKERBRAUN, Brian** [US/US]; 108 Maple Heights Road, Pittsburgh, PA 15232 (US).
- Published:**  
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHODS OF TREATING VASCULAR DISEASE

(57) Abstract: The present invention relates to a method of treating patients suffering from, or at risk for, intimal hyperplasia and/or arteriosclerosis. The treatment includes administering a pharmaceutical composition that includes carbon monoxide to the patient.



**WO 03/072024 A2**

## METHODS OF TREATING VASCULAR DISEASE

### Cross-Reference to Related Applications

This application claims priority to U.S. Provisional Application No. 60/356,718 filed February 13, 2002, which is incorporated herein by reference in its entirety.

5

### Statement as to Federally Sponsored Research

This invention was made with Government support under National Institutes of Health Grant Nos. HL55330, HL60234, HL67040, HL58688, HL53458, HL60234, HL5785405, and AI42365. The Government has certain rights in this invention.

10

### Technical Field

This invention generally relates to treating vascular disease.

### Background

15

Heme oxygenase-1 (HO-1) catalyzes the first step in the degradation of heme. HO-1 cleaves the  $\alpha$ -meso carbon bridge of b-type heme molecules by oxidation to yield equimolar quantities of biliverdin IXa, carbon monoxide (CO), and free iron.

Subsequently, biliverdin is converted to bilirubin via biliverdin reductase, and the free iron is sequestered into ferritin (the production of which is induced by the free iron).

20

CO is recognized as an important signaling molecule (Verma *et al.*, Science 259:381-384, 1993). It has been suggested that carbon monoxide acts as a neuronal messenger molecule in the brain (*Id.*) and as a neuro-endocrine modulator in the hypothalamus (Pozzoli *et al.*, Endocrinology 735:2314-2317, 1994). Like nitric oxide, CO is a smooth muscle relaxant (Utz *et al.*, Biochem Pharmacol. 47:195-201, 1991; Christodoulides *et al.*, Circulation 97:2306-9, 1995) and inhibits platelet aggregation (Mansouri *et al.*, Thromb Haemost. 48:286-8, 1982). Inhalation of low levels of CO

25

has been shown to have anti-inflammatory effects in some models.

Intimal hyperplasia, a thickening of the inner layer of the blood vessel, is a pathological process that arises from vascular injury subsequent to procedures such as angioplasty, bypass surgery or organ transplantation. Intimal hyperplasia continues to limit the success of these therapeutic interventions.

### Summary

The present invention is based, in part, on the discoveries that CO prevents arteriosclerotic lesions and intimal hyperplasia following aortic transplant and carotid artery balloon injury in animals.

5       Accordingly, in one aspect, the invention provides a method of treating intimal hyperplasia in a patient. The method includes identifying a patient suffering from or at risk for intimal hyperplasia (e.g., intimal hyperplasia resulting from an angioplasty procedure or a transplant procedure, or resulting from a procedure or condition other than a transplant procedure), and administering to the patient a pharmaceutical  
10       composition comprising an amount of carbon monoxide effective to treat intimal hyperplasia in the patient.

      The invention also provides a method of performing angioplasty in a patient. The method includes performing angioplasty in the patient, and before, during, and/or after performing angioplasty, administering to the patient a pharmaceutical composition  
15       comprising an amount of CO effective to treat intimal hyperplasia in the patient. The angioplasty can be any angioplasty procedure, e.g., balloon angioplasty; laser angioplasty; artherectomy, e.g., directional atherectomy, rotational atherectomy, or extraction atherectomy; and/or any angioplasty procedure using a stent, or any combination of such procedures.

20       The invention also provides a method of treating (e.g., preventing or decreasing) restenosis in a patient. The method includes providing a vessel containing a pressurized gas comprising carbon monoxide gas, identifying a patient suffering from or at risk for restenosis, releasing the pressurized gas from the vessel to form an atmosphere comprising carbon monoxide gas, and exposing the patient to the  
25       atmosphere, wherein the amount of carbon monoxide in the atmosphere is sufficient to treat restenosis in the patient.

      In another aspect, the invention provides a method of treating restenosis in a patient. The method includes identifying a patient suffering from or at risk for restenosis and administering to the patient a pharmaceutical composition comprising an  
30       amount of carbon monoxide effective to treat restenosis in the patient. Restenosis can result from any angioplasty procedure, e.g., balloon angioplasty; laser angioplasty; artherectomy, e.g., directional atherectomy, rotational atherectomy, or extraction

atherectomy; and/or any angioplasty procedure using a stent, or any combination of such procedures.

The invention also provides a method for performing vascular surgery, e.g., a transplant procedure, on a patient. The method includes: (a) performing vascular  
5 surgery (e.g., a transplant procedure) on a patient, and (b) before during and/or after (a), administering to the patient a pharmaceutical composition comprising an amount of CO effective to treat arteriosclerosis (e.g., intimal hyperplasia) in the patient.

In another aspect, the invention provides a method of inhibiting smooth muscle cell proliferation. The method includes providing a smooth muscle cell(s), and  
10 administering to the smooth muscle cell(s) an amount of CO effective to inhibit proliferation of the smooth muscle muscle cell(s). This can be carried out *in vivo* or *in vitro*.

A method of performing angioplasty in a patient is also provided, which includes providing an angioplasty device (e.g., a device described herein) capable of  
15 administering carbon monoxide to a patient, positioning the device in a blood vessel in need of angioplasty, performing angioplasty using the device, and before, during and/or after performing angioplasty, administering CO to the blood vessel using the device in an amount sufficient to treat intimal hyperplasia, to thereby perform angioplasty in the patient. The device can be any device capable of use in an angioplasty procedure, e.g.,  
20 a device described herein. Alternatively or in addition, the device can be coated with a CO-releasing agent, e.g., a hydrogel, oil, or ointment, that releases CO or a CO-releasing compound.

In another aspect, the invention provides a vessel comprising medical grade compressed CO gas. The vessel can bear a label indicating that the gas can be used to  
25 reduce restenosis, arteriosclerosis, and/or intimal hyperplasia in a patient (e.g., a human patient), and/or that it can be used in an angioplasty procedure. The CO gas can be in an admixture with nitrogen gas, with nitric oxide and nitrogen gas, or with an oxygen-containing gas. The CO gas can be present in the admixture at a concentration of at least about 0.025%, e.g., at least about 0.05%, 0.10%, 0.50%, 1.0%, 2.0%, 10%,  
30 50%, or 90%.

The invention also provides a kit that includes an angioplasty device (e.g., a balloon angioplasty device; a laser angioplasty device; an atherectomy device; and/or a stent) and a vessel containing CO (e.g., a liquid and/or gaseous CO composition). The

angioplasty device is capable of administering carbon monoxide to a patient. The kit can further include instructions for use of the carbon monoxide composition in a method for performing angioplasty in a patient.

In another aspect, the invention provides angioplasty devices (e.g., balloon  
5 angioplasty devices, laser angioplasty devices, atherectomy devices, and stents, e.g., a device described herein) capable of administering CO to a patient and/or a blood vessel immediately before, during, and/or after an angioplasty procedure. In one embodiment, the angioplasty device comprises a CO composition. In another embodiment, the device is a balloon angioplasty device that includes an inflatable member (e.g., a  
10 balloon) having a plurality of apertures, and a reservoir containing CO (e.g., a liquid or gaseous CO composition) connected to the inflatable member, such that CO can be delivered from the reservoir through the inflatable member and to the blood vessel.

Also within the invention is the use of CO in the manufacture of a medicament for treatment or prevention of a condition described herein, e.g., intimal hyperplasia,  
15 restenosis, and/or arteriosclerosis. The medicament can also be used in a method for performing an angioplasty procedure and/or a transplantation procedure. The medicament can be in any form as described herein, e.g., a liquid or gaseous CO composition.

Unless otherwise defined, all technical and scientific terms used herein have the  
20 same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Suitable methods and materials are described below, although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their  
25 entirety. In case of conflict, the present specification, including definitions, will control. The materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

### 30 Brief Description of the Drawings

Fig. 1A is a photomicrograph (50X magnification) of a syngeneically transplanted aortic graft illustrating the effect of syngeneic transplantation on the graft.

Fig. 1B is a photomicrograph (50X magnification) of an allogeneically transplanted aortic graft illustrating the effect of allogeneic transplantation on the graft.

Fig. 1C is a photomicrograph (50X magnification) of an allogeneically transplanted aortic graft illustrating the effect of allogeneic transplantation on the graft  
5 when the recipient is exposed to CO.

Fig. 1D is a photomicrograph (200X magnification ) of a syngeneically transplanted aortic graft illustrating the effect of syngeneic transplantation on the graft.

Fig. 1E is a photomicrograph (200X magnification) of an allogeneically transplanted aortic graft illustrating the effect of allogeneic transplantation on the graft.

10 Fig. 1F is a photomicrograph (200X magnification) of an allogeneically transplanted aortic graft illustrating the effect of allogeneic transplantation on the graft when the recipient is exposed to CO.

Fig. 1G is a bar graph illustrating the mean relative areas (in arbitrary units) of the intima of aortic grafts transplanted syngeneically into air-exposed recipients  
15 (Syng.), allogeneically into air-exposed recipients (Allo.), and allogeneically into CO-exposed recipients (Allo. + CO).

Fig. 1H is a bar graph illustrating the mean relative areas (in arbitrary units) of the media of aortic grafts transplanted syngeneically into air-exposed recipients  
20 (Syng.), allogeneically into air-exposed recipients (Allo.), and allogeneically into CO-exposed recipients (Allo. + CO).

Fig. 1I is a bar graph illustrating the intima/media area ratio of aortic grafts transplanted syngeneically into air-exposed recipients (Syng.), allogeneically into air-exposed recipients (Allo.), and allogeneically into CO-exposed recipients (Allo. + CO).

Fig. 2A is a bar graph illustrating accumulation of activated leukocytes  
25 (measured by counting total nuclei) in the adventitia of aortic grafts transplanted syngeneically into air-exposed recipients (Syngeneic), allogeneically into air-exposed recipients (Allogeneic) and allogeneically into recipients exposed to various concentrations of CO (CO 250 ppm; CO 500 ppm; and CO 750-1000 ppm).

Fig. 2B is a set of bar graphs illustrating accumulation of CD45, ED1, MHCII,  
30 and CD54 positive cells in the adventitia of aortic grafts transplanted syngeneically into air-exposed recipients (Syng.), allogeneically into air-exposed recipients (Allog.), and allogeneically into CO-exposed recipients (Allo. + CO).

Fig. 2C is a set of bar graphs illustrating accumulation of CD3, CD4, and CD8 positive cells in the adventitia of aortic grafts transplanted syngeneically into air-exposed recipients (Syng.), allogeneically into air-exposed recipients (Allog.), and allogeneically into CO-exposed recipients (Allo. + CO).

5 Fig. 3A is a photomicrograph (10X magnification) of a carotid artery sample illustrating the effect of balloon angioplasty on the artery.

Fig. 3B is a photomicrograph (10X magnification) of a carotid artery sample illustrating the effect of balloon angioplasty on the artery when the subject is pre-exposed to CO.

10 Fig 3C is a photomicrograph of a carotid artery sample illustrating the effect of balloon angioplasty on the artery.

Fig. 3D is a photomicrograph of a carotid artery sample illustrating the effect of balloon angioplasty on the artery when the subject is pre-exposed to CO.

15 Fig. 3E is a bar graph illustrating the mean relative areas (in arbitrary units) of the intima of carotid arteries subjected to balloon angioplasty when the subject animal is pre-exposed either to air (Control) or 250 ppm CO (CO).

Fig. 3F is a bar graph illustrating the mean relative areas (in arbitrary units) of the media of carotid arteries subjected to balloon angioplasty when the subject animal is pre-exposed either to air (Control) or 250 ppm CO (CO).

20 Fig. 3G is a bar graph illustrating the intima/media area ratio of carotid arteries subjected to balloon angioplasty when the subject animal is pre-exposed either to air (Control) or 250 ppm CO (CO).

Fig. 4A is a line graph illustrating proliferation of rat SMC that were non-transduced ( $\circ$ ; Medium), transduced with Lac.Z recombinant adenovirus ( $\square$ ; LacZ Rec. Ad.) or transduced with HO-1 recombinant adenovirus ( $\bullet$ ; HO-1 rec. Ad.).

Fig. 4B is a line graph illustrating proliferation of rat SMC in the presence ( $\bullet$ ; 1000 ppm) or absence ( $\square$ ) of CO.

Fig. 4C is a bar graph illustrating proliferation of SMC isolated from wild type (WT) or HO-1 deficient ( $ho-1^{-/-}$ ) mice in the presence (CO) and absence (Air) of CO.

30 Fig. 4D is a Western blot illustrating the effect of CO exposure (for 0, 4, 5, 16, and 24 hours) on p21 and  $\beta$ -actin protein expression in mouse SMC.

Fig. 4E is a bar graph illustrating the effect of CO on proliferation of mouse SMC isolated from wild type (wt), p21Cip1 ( $p21^{-/-}$ ) and p53 ( $p53^{-/-}$ ) deficient mice.

Gray bars indicate cells exposed to room air and black bars cells exposed to CO (250 ppm).

Fig. 4F is a bar graph illustrating the intima/media area ratio of balloon-injured carotid arteries from wild type (C57/Bl6/S129; wt) and *p21*<sup>-/-</sup> mice exposed to air (Air) or carbon monoxide (CO).

Fig. 5A is a bar graph illustrating the effect of air (Air) and CO (250 ppm for 8 h or 16 h) exposure on the mean cellular cGMP content of mouse SMCs.

Fig. 5B is a bar graph illustrating [<sup>3</sup>H]thymidine uptake by mouse SMCs exposed to air (Air), CO (250 ppm) and CO plus the guanylate cyclase inhibitor 1H(1,2,4) Oxadiazolo(4,3-a) Quinoxalin-1 (CO/ODQ).

Fig. 5C is a composite picture of a Western blot illustrating the effect of 8-Bromoguanosine 3'-5'-cyclic monophosphate sodium salt (8-Br-cGMP) on p21<sup>Cip1</sup> expression.

Fig. 5D is a bar graph illustrating [<sup>3</sup>H]thymidine uptake by SMC isolated from wild type (wt) and p21<sup>Cip1</sup> (*p21*<sup>-/-</sup>) deficient mice in the presence (8Br-cGMP; 8Br-cGMP (*p21*<sup>-/-</sup>)) and absence (Air) of the cGMP analogue 8Br-cGMP.

Fig. 5E is a composite picture of a Western blot illustrating the effect of CO (250 ppm) on expression of phosphorylated p38 MAPK (p-p38), ATF-2 (p-ATF-2), JNK (p-JNK) and ERK (p-ERK) as compared to total p38 MAPK, ATF-2, JNK, and ERK in SMC.

Fig. 5F is a bar graph illustrating [<sup>3</sup>H]thymidine uptake by mouse SMC exposed air (Air) 250 ppm CO (CO) and CO plus the p38 MAPK inhibitor SB203580 (CO/SB).

Fig. 5G is a composite picture of a Western blot illustrating the effect of air (Air), CO (250 ppm; CO)), SB203580, and DMSO on expression of p21<sup>Cip1</sup> in mouse SMC.

Fig. 6A is a composite picture of a Western blot illustrating the effect of 8-Br-cGMP on expression of p38 MAPK in mouse SMC.

Fig. 6B is a bar graph illustrating [<sup>3</sup>H]thymidine uptake by mouse SMC exposed to air (Air), CO plus 8-Br-cGMP (8-Br-cGMP), and CO plus 8-Br-cGMP plus SB203580 (8-Br-cGMP + SB203580).

Fig. 7A is a flow cytometry plot illustrating the effect of air (Air) and CO (250 ppm) exposure on the cell cycle of rat aortic SMC.



Fig. 7B is a line graph illustrating the effect of air (□) and CO (■) on SMC proliferation.

Fig. 8 is a bar graph illustrating [ $^3\text{H}$ ]thymidine uptake by wild type (wt),  $p21^{-/-}$ , and  $p53^{-/-}$  mouse SMC exposed to either air (gray bars) or to CO (250 ppm; black bars) for 24 hours.

Fig. 9A is a photomicrograph (20x magnification) of a carotid artery section from a wild type mouse 14 days after wire injury. The subject animal was exposed to room air for 1 h prior to wire injury.

Fig. 9B is a photomicrograph (20x magnification) of a carotid artery section from a wild type mouse 14 days after wire injury. The subject animal was exposed to CO (250 ppm) for 1 h prior to wire injury.

Fig. 9C is a photomicrograph (20x magnification) of a carotid artery section from a  $p21^{-/-}$  mouse 14 days after wire injury. The subject animal was exposed to room air for 1 h prior to wire injury.

Fig. 9D is a photomicrograph (20x magnification) of a carotid artery section from a  $p21^{-/-}$  mouse 14 days after being subjected to wire injury. The subject animal was exposed to CO (250 ppm) for 1 h prior to wire injury.

Fig. 9E is a bar graph illustrating the mean relative areas (in arbitrary units) of the intima of wire-injured carotid arteries from wild type (wt) and  $p21^{-/-}$  mice exposed to either air (Control) or 250 ppm CO (CO).

Fig. 9F is a bar graph illustrating the mean relative areas (in arbitrary units) of the media of wire-injured carotid arteries from wild type (wt) and  $p21^{-/-}$  mice exposed to either air (Control) or 250 ppm CO (CO).

Fig. 9G is a bar graph illustrating the intima/media area ratio of wire-injured carotid arteries from wild type (wt) and  $p21^{-/-}$  mice exposed to either air (Control) or 250 ppm CO (CO).

Fig. 10 is a bar graph illustrating [ $^3\text{H}$ ]thymidine uptake by  $p21^{-/-}$  mouse-derived SMC treated with air (Air), CO (250 ppm; CO) and CO plus SB203580 (CO/SB).

Fig. 11A is a bar graph illustrating [ $^3\text{H}$ ]thymidine uptake by wild type (wt),  $enos^{-/-}$ , and  $inos^{-/-}$  deficient mouse-derived SMC exposed to air (Air) or CO (250 ppm; CO).

Fig. 11B is a bar graph illustrating the mean intimal and media areas, and the intima/media area ratios, of carotid arteries from Sprague-Dawley rats exposed to room air (white bars) or NO (Black bars; 1 hour; 250 ppm) prior to balloon injury of the carotid artery.

5 Fig. 12A is a composite picture of a Western blot illustrating PAI-1 expression in SMC treated with and without serum (Serum and No Serum, respectively) and with and without CO (Air and CO, respectively) for 24 or 48 hours. Liver = whole cell lysates from rat liver homogenates treated without endotoxin (LPS). Liver + LPS = whole cell lysates from rat liver homogenates treated with endotoxin (LPS). TNF- $\alpha$  =  
10 control wherein TNF- $\alpha$  was added to the cell culture to stimulate expression of PAI-1.

Fig. 12B is a picture of a Western blot illustrating PAI-1 expression in untransplanted (control), transplanted (Allo. + Air), and CO-treated transplanted (Allo. + CO) aortas 56 days after transplantation.

Fig. 12C is a picture of a Commassie blue stained polyacrylamide gel used for  
15 the Western blot of Fig. 12B, which illustrates PAI-expression in untransplanted (control), transplanted (Allo. + Air), and CO-treated transplanted (Allo. + CO) aortas 56 days after transplantation.

Figs. 13A-13B illustrate an example of balloon angioplasty device capable of administering CO to a patient during an angioplasty procedure, at various stages of  
20 operation.

Figs. 13C-13D illustrate alternative embodiments of the balloon angioplasty device.

Figs. 14A-14B illustrate an example of a stent capable of administering CO to a patient during an angioplasty procedure, at various stages of operation.

25 Fig. 15 illustrates an example of balloon angioplasty device with multiple balloons designed to administer CO to a patient during an angioplasty procedure.

Fig 16 illustrates an example of an atherectomy device capable of administering CO to a patient during an angioplasty procedure.

### 30 Detailed Description

The term “carbon monoxide” (or “CO”) as used herein describes molecular carbon monoxide in its gaseous state, compressed into liquid form, or dissolved in

aqueous solution. The term “carbon monoxide composition” or “pharmaceutical composition comprising carbon monoxide” is used throughout the specification to describe a gaseous or liquid composition containing carbon monoxide that can be administered to a patient and/or a blood vessel, e.g., a patient (or blood vessel) subjected to angioplasty, bypass surgery, transplant, or any other procedure that may/will result in intimal hyperplasia and/or arteriosclerosis. A skilled practitioner will recognize which form of the pharmaceutical composition, *e.g.*, gaseous, liquid, or both gaseous and liquid forms, is preferred for a given application.

The term “intimal hyperplasia” is an art-recognized term and is used herein to refer to proliferation of cells, *e.g.*, smooth muscle cells, within the intima of a blood vessel. The skilled practitioner will appreciate that intimal hyperplasia can be caused by any number of factors, *e.g.*, mechanical, chemical and/or immunological damage to the intima. Intimal hyperplasia can often be observed in patients, for example, following balloon angioplasty or vascular surgery, *e.g.*, vascular surgery involving vein grafts (e.g., transplant surgery). “Arteriosclerosis,” “arteriosclerotic lesion,” “arteriosclerotic plaque,” and “arteriosclerotic condition” are also art recognized term terms, and are used herein to describe a thickening and hardening of the arterial wall. The term “vasculature” as used herein refers to the vascular system (or any part thereof) of a body, human or non-human, and includes blood vessels, *e.g.*, arteries, arterioles, veins, venules, and capillaries. The term “restenosis” refers to re-narrowing of an artery following angioplasty.

The term “angioplasty” is an art-recognized term and refers to any procedure, singly or in combination, involving remodeling of a blood vessel, *e.g.*, dilating a stenotic region in a patient’s vasculature to restore adequate blood flow beyond the stenosis. Such procedures include percutaneous transluminal angioplasty (PTA), which employs a catheter having an expansible distal end, *i.e.*, an inflatable balloon (known as “balloon angioplasty”); laser angioplasty; extraction atherectomy; directional atherectomy; rotational atherectomy; stenting; and any other procedure for remodeling a blood vessel, *e.g.*, an artery.

The terms “effective amount” and “effective to treat,” as used herein, refer to an amount or a concentration of carbon monoxide utilized for a period of time (including acute or chronic administration and periodic or continuous administration) that is effective within the context of its administration for causing an intended effect or

physiological outcome. Effective amounts of carbon monoxide for use in the present invention include, for example, amounts that prevent or reduce intimal hyperplasia following a procedure, e.g., angioplasty. Effective amounts of carbon monoxide also include amounts that prevent or reduce arteriosclerosis in a patient, e.g., a transplant  
5 patient. The term “treat(ment)” is used herein to describe delaying the onset of, inhibiting, or alleviating the detrimental effects of a condition, e.g., intimal hyperplasia and/or arteriosclerosis.

For gases, effective amounts of CO generally fall within the range of about 0.0000001% to about 0.3% by weight, e.g., 0.0001% to about 0.25% by weight,  
10 preferably at least about 0.001%, e.g., at least about 0.005%, 0.010%, 0.02%, 0.025%, 0.03%, 0.04%, 0.05%, 0.06%, 0.08%, 0.10%, 0.15%, 0.20%, 0.22%, or 0.24% by weight of CO. Preferred ranges of CO include 0.002% to about 0.24%, about 0.005% to about 0.22%, about 0.01% to about 0.20%, and about 0.02% to about 0.1% by weight. For liquid solutions of CO, effective amounts generally fall within the range of  
15 about 0.0001 to about 0.0044 g CO/100 g liquid, e.g., at least about 0.0001, 0.0002, 0.0004, 0.0006, 0.0008, 0.0010, 0.0013, 0.0014, 0.0015, 0.0016, 0.0018, 0.0020, 0.0021, 0.0022, 0.0024, 0.0026, 0.0028, 0.0030, 0.0032, 0.0035, 0.0037, 0.0040, or 0.0042 g CO/100 g aqueous solution. Preferred ranges include, e.g., about 0.0010 to about 0.0030 g CO/100 g liquid, about 0.0015 to about 0.0026 g CO/100 g liquid, or  
20 about 0.0018 to about 0.0024 g CO/100 g liquid. A skilled practitioner will appreciate that amounts outside of these ranges may be used depending upon the application.

The term “patient” is used throughout the specification to describe an animal, human or non-human, to whom treatment according to the methods of the present invention is provided. Veterinary and non-veterinary applications are contemplated by  
25 the present invention. The term includes but is not limited to mammals, e.g., humans, other primates, pigs, rodents such as mice and rats, rabbits, guinea pigs, hamsters, cows, horses, cats, dogs, sheep and goats.

The term “transplantation” is used throughout the specification as a general term to describe the process of transferring an organ or tissue into a patient. The term  
30 “transplantation” is defined in the art as the transfer of living tissues or cells from a donor to a recipient, with the intention of maintaining the functional integrity of the transplanted tissue or cells in the recipient (see, e.g., *The Merck Manual*, Berkow, Fletcher, and Beers, Eds., Merck Research Laboratories, Rahway, N.J., 1992). The

term includes all categories of transplants known in the art. Transplants are categorized by site and genetic relationship between donor and recipient. The term includes, *e.g.*, autotransplantation (removal and transfer of cells or tissue from one location on a patient to the same or another location on the same patient), allotransplantation  
5 (transplantation between members of the same species), and xenotransplantation (transplantations between members of different species).

The term “donor” or “donor patient” as used herein refers to an animal (human or non-human) from whom an organ or tissue can be obtained for the purposes of transplantation to a recipient patient. The term “recipient” or “recipient patient” refers  
10 to an animal (human or non-human) into which an organ or tissue can be transferred.

The terms “organ rejection”, “transplant rejection” and “rejection” are art-recognized and are used throughout the specification as general terms to describe the process of rejection of an organ, tissues, or cells in a recipient. Included within the definition are, for example, three main patterns of rejection that are typically identified  
15 in clinical practice: hyperacute rejection, acute rejection, and chronic rejection (see, *e.g.*, *Oxford Textbook of Surgery*, Morris and Malt, Eds., Oxford University Press (1994)).

The term “organ(s)” is used throughout the specification as a general term to describe any anatomical part or member having a specific function in the animal.  
20 Further included within the meaning of this term are substantial portions of organs, *e.g.*, cohesive tissues obtained from an organ. Such organs include but are not limited to kidney, liver, heart, intestine, *e.g.*, large or small intestine, pancreas, and lungs. Also included in this definition is vasculature, *e.g.*, veins and arteries, and bones.

Individuals considered at risk for developing intimal hyperplasia or  
25 arteriosclerosis may benefit particularly from the invention, primarily because prophylactic CO treatment can be administered before a procedure is performed on a patient or before there is any evidence of intimal hyperplasia or an arteriosclerotic plaque. Individuals “at risk” include, *e.g.*, patients that have or will have any type of mechanical, chemical and/or immunological damage to the intima, *e.g.*, patients that  
30 will or have undergone transplant surgery and/or angioplasty. Skilled practitioners will appreciate that a patient can be determined to be at risk for intimal hyperplasia or arteriosclerosis by any method known in the art, *e.g.*, by a physician’s diagnosis.

### Preparation of Gaseous Compositions

A CO composition may be a gaseous composition. Compressed or pressurized gas useful in the methods of the invention can be obtained from any commercial source, and in any type of vessel appropriate for storing compressed gas. For example, 5 compressed or pressurized gases can be obtained from any source that supplies compressed gases, such as oxygen, for medical use. The term “medical grade” gas, as used herein, refers to gas suitable for administration to patients as defined herein. The pressurized gas including CO used in the methods of the present invention can be provided such that all gases of the desired final composition (e.g., CO, He, NO, CO<sub>2</sub>, 10 O<sub>2</sub>, N<sub>2</sub>) are in the same vessel, except that NO and O<sub>2</sub> cannot be stored together. Optionally, the methods of the present invention can be performed using multiple vessels containing individual gases. For example, a single vessel can be provided that contains carbon monoxide, with or without other gases, the contents of which can be optionally mixed with the contents of other vessels, e.g., vessels containing oxygen, 15 nitrogen, carbon dioxide, compressed air, or any other suitable gas or mixtures thereof.

Gaseous compositions administered to a patient according to the present invention typically contain 0% to about 79% by weight nitrogen, about 21% to about 100% by weight oxygen and about 0.0000001% to about 0.3% by weight (corresponding to about 1 ppb or 0.001 ppm to about 3,000 ppm) CO. Preferably, the 20 amount of nitrogen in the gaseous composition is about 79% by weight, the amount of oxygen is about 21% by weight and the amount of CO is about 0.0001% to about 0.25% by weight. The amount of CO is preferably at least about 0.001%, e.g., at least about 0.005%, 0.01%, 0.02%, 0.025%, 0.03%, 0.04%, 0.05%, 0.06%, 0.08%, 0.10%, 0.15%, 0.20%, 0.22%, or 0.24% by weight. Preferred ranges of CO include 0.005% to 25 about 0.24%, about 0.01% to about 0.22%, about 0.015% to about 0.20%, and about 0.025% to about 0.1% by weight. It is noted that gaseous CO compositions having concentrations of CO greater than 0.3% (such as 1% or greater) may be used for short periods (e.g., one or a few breaths), depending upon the application.

A gaseous CO composition may be used to create an atmosphere that comprises 30 CO gas. An atmosphere that includes appropriate levels of CO gas can be created, for example, by providing a vessel containing a pressurized gas comprising CO gas, and releasing the pressurized gas from the vessel into a chamber or space to form an atmosphere that includes the CO gas inside the chamber or space. Alternatively, the

gases can be released into an apparatus that culminates in a breathing mask or breathing tube, thereby creating an atmosphere comprising CO gas in the breathing mask or breathing tube, ensuring the patient is the only person in the room exposed to significant levels of CO.

5 CO levels in an atmosphere can be measured or monitored using any method known in the art. Such methods include electrochemical detection, gas chromatography, radioisotope counting, infrared absorption, colorimetry, and electrochemical methods based on selective membranes (see, e.g., Sunderman *et al.*, Clin. Chem. 28:2026-2032, 1982; Ingi *et al.*, Neuron 16:835-842, 1996). Sub-parts per  
10 million CO levels can be detected by, e.g., gas chromatography and radioisotope counting. Further, it is known in the art that CO levels in the sub-ppm range can be measured in biological tissue by a midinfrared gas sensor (see, e.g., Morimoto *et al.*, Am. J. Physiol. Heart. Circ. Physiol 280:H482-H488, 2001). CO sensors and gas detection devices are widely available from many commercial sources.

15

#### Preparation of Liquid Compositions

A pharmaceutical composition comprising CO may also be a liquid composition. A liquid can be made into a pharmaceutical composition comprising CO by any method known in the art for causing gases to become dissolved in liquids. For  
20 example, the liquid can be placed in a so-called "CO<sub>2</sub> incubator" and exposed to a continuous flow of CO, preferably balanced with carbon dioxide, until a desired concentration of CO is reached in the liquid. As another example, CO gas can be "bubbled" directly into the liquid until the desired concentration of CO in the liquid is reached. The amount of CO that can be dissolved in a given aqueous solution increases  
25 with decreasing temperature. As still another example, an appropriate liquid may be passed through tubing that allows gas diffusion, where the tubing runs through an atmosphere comprising CO (e.g., utilizing a device such as an extracorporeal membrane oxygenator). The CO diffuses into the liquid to create a liquid CO composition.

30 It is likely that such a liquid composition intended to be introduced into a living animal will be at or about 37°C at the time it is introduced into the animal.

The liquid can be any liquid known to those of skill in the art to be suitable for administration to patients (see, for example, Oxford Textbook of Surgery, Morris and

Malt, Eds., Oxford University Press (1994)). In general, the liquid will be an aqueous solution. Examples of solutions include Phosphate Buffered Saline (PBS), Celsior™, Perfadex™, Collins solution, citrate solution, and University of Wisconsin (UW) solution (Oxford Textbook of Surgery, Morris and Malt, Eds., Oxford University Press  
5 (1994)). In one embodiment of the present invention, the liquid is Ringer's Solution, e.g., lactated Ringer's Solution, or any other liquid that can be used infused into a patient. In another embodiment, the liquid includes blood, e.g., whole blood.

Any suitable liquid can be saturated to a set concentration of CO via gas diffusers. Alternatively, pre-made solutions that have been quality controlled to  
10 contain set levels of CO can be used. Accurate control of dose can be achieved via measurements with a gas permeable, liquid impermeable membrane connected to a CO analyzer. Solutions can be saturated to desired effective concentrations and maintained at these levels.

#### 15 Treatment of Patients and Vasculature with CO Compositions

The present invention contemplates administering CO compositions to patients and/or portions of their vasculature before, during, and/or after the patient undergoes angioplasty, transplant surgery, vascular surgery, or any other procedure that causes/increases the risk of intimal hyperplasia, restenosis, and/or arteriosclerosis in the  
20 patient. A patient can be treated systemically with gaseous and/or liquid CO compositions by any method known in the art for administering gases and/or liquids to patients, e.g., by inhalation of the gas and intravenous or intraarterial administration of the liquid. With systemic treatment, substantially all of the patient's vasculature can be treated with CO. A portion of a patient's vasculature, e.g., a specific vein or artery, can  
25 be treated by administering a gaseous or liquid CO composition directly to the vein or artery. Although the present invention is not limited to any particular mode for administering CO compositions to patients and/or portions of their vasculature, various treatments are discussed in detail below.

#### 30 Systemic Delivery of Gaseous CO

Gaseous CO compositions can be delivered systemically to a patient, e.g., a patient suffering from or at risk for intimal hyperplasia (e.g., restenosis and/or arteriosclerosis). Gaseous CO compositions are typically administered by inhalation



through the mouth or nasal passages to the lungs, where the CO is readily absorbed into the patient's bloodstream. The concentration of active compound (CO) utilized in the therapeutic gaseous composition will depend on absorption, distribution, inactivation, and excretion (generally, through respiration) rates of the CO as well as other factors  
5 known to those of skill in the art. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of  
10 the claimed composition. Acute, sub-acute and chronic administration of CO are contemplated by the present invention. CO can be delivered to the patient for a time (including indefinitely) sufficient to treat the condition and exert the intended pharmacological or biological effect.

The following are examples of some methods and devices that can be utilized to  
15 administer gaseous CO compositions to patients.

### *Ventilators*

Medical grade CO (concentrations can vary) can be purchased mixed with air or another oxygen-containing gas in a standard tank of compressed gas (e.g., 21% O<sub>2</sub>,  
20 79% N<sub>2</sub>). It is non-reactive, and the concentrations that are required for the methods of the present invention are well below the combustible range (10% in air). In a hospital setting, the gas presumably will be delivered to the bedside where it will be mixed with oxygen or house air in a blender to a desired concentration in ppm (parts per million). The patient will inhale the gas mixture through a ventilator, which will be set to a flow  
25 rate based on patient comfort and needs. This is determined by pulmonary graphics (i.e., respiratory rate, tidal volumes etc.). Fail-safe mechanism(s) to prevent the patient from unnecessarily receiving greater than desired amounts of carbon monoxide can be designed into the delivery system. The patient's CO level can be monitored by studying (1) carboxyhemoglobin (COHb), which can be measured in venous blood, and  
30 (2) exhaled CO collected from a side port of the ventilator. CO exposure can be adjusted based upon the patient's health status and on the basis of the markers. If necessary, CO can be washed out of the patient by switching to 100% O<sub>2</sub> inhalation. CO is not metabolized; thus, whatever is inhaled will ultimately be exhaled except for a

very small percentage that is converted to CO<sub>2</sub>. CO can also be mixed with any level of O<sub>2</sub> to provide therapeutic delivery of CO without consequential hypoxic conditions.

#### *Face Mask and Tent*

5 A CO-containing gas mixture is prepared as above to allow passive inhalation by the patient using a facemask or tent. The concentration inhaled can be changed and can be washed out by simply switching over to 100% O<sub>2</sub>. Monitoring of CO levels would occur at or near the mask or tent with a fail-safe mechanism that would prevent too high of a concentration of CO from being inhaled.

#### *Portable inhaler*

Compressed CO can be packaged into a portable inhaler device and inhaled in a metered dose, for example, to permit intermittent treatment of a recipient who is not in a hospital setting. Different concentrations of CO could be packaged in the containers.

15 The device could be as simple as a small tank (e.g., under 5 kg) of appropriately diluted CO with an on-off valve and a tube from which the patient takes a whiff of CO according to a standard regimen or as needed.

#### *Intravenous Artificial Lung*

20 An artificial lung (a catheter device for gas exchange in the blood) designed for O<sub>2</sub> delivery and CO<sub>2</sub> removal can be used for CO delivery. The catheter, when implanted, resides in one of the large veins and would be able to deliver CO at desired concentrations either for systemic delivery or at a local site. The delivery can be a local delivery of a high concentration of CO for a short period of time at the site of an angioplastic procedure (this high concentration would rapidly be diluted out in the bloodstream), or a relatively longer exposure to a lower concentration of CO.

Examples of an artificial lungs are described, e.g., in Hattler *et al.*, *Artif. Organs* 18(11):806-812 (1994); and Golob *et al.*, *ASAIO J.*, 47(5):432-437 (2001). As used herein, the term "intravessel carbon monoxide delivery device" refers to a catheter

30 device, e.g., an artificial lung (or modified version thereof) capable of residing in a blood vessel for extended periods of time (including indefinitely) and delivering CO to the patient systemically and/or locally.

*Normobaric chamber*

In certain instances, it would be desirable to expose the whole patient to CO. The patient would be inside an airtight chamber that would be flooded with CO at a level that does not endanger the patient, or at a level that poses an acceptable risk without the risk of bystanders' being exposed. Upon completion of the exposure, the chamber could be flushed with air (e.g., 21% O<sub>2</sub>, 79% N<sub>2</sub>) and samples could be analyzed by CO analyzers to ensure no CO remains before allowing the patient to exit the exposure system.

Systemic Delivery of Liquid CO Compositions

The present invention further contemplates that liquid CO compositions can be created for systemic delivery to a patient, e.g., by intravenous or intraarterial infusion into a patient. For example, liquid CO compositions, such as CO-saturated Ringer's Solution, can be infused into a patient before, during, and/or after an angioplastic or transplant procedure. Alternatively or in addition, CO-partially or completely saturated whole (or partial) blood can be infused into the patient. The present invention also contemplates that agents capable of delivering doses of CO gas or liquids can be utilized (e.g., CO releasing gums, creams, ointments or patches).

Delivery of CO to Portions of the Vasculature*In Situ Treatment*

Alternatively or in addition to systemic treatment, carbon monoxide compositions can be applied directly to any portion of a patient's vasculature that has or is at risk for intimal hyperplasia and/or arteriosclerosis. A gaseous composition can be applied directly to a portion of a patient's vasculature, e.g., to an affected artery, by any method known in the art for administering gases into a patient's vasculature. For example, CO can be delivered to an artery before, during, and/or after an angioplastic (e.g., balloon angioplasty) or surgical (e.g., transplant) procedure through a device similar to the intravenous artificial lung described above. As another example, any device used for performing an angioplastic procedure can be modified to administer CO to a patient's vasculature through the instrument while angioplasty is being performed. Such devices are discussed in further detail below.

Liquid CO compositions can also be applied directly to a portion of a patient's vasculature. Liquid CO compositions can be administered by any method known in the art for administering liquids to the vasculature of a patient. For example, a liquid CO composition can be administered to a specific vein (e.g., by intravenous injection) or artery (e.g., by intraarterial injection) before, during, and/or after a procedure. As another example, as described above, any instrument used in angioplastic procedures can be modified to administer to a vein or artery a liquid CO composition while an angioplastic procedure is being performed.

#### *Ex Vivo Treatment*

The present invention further contemplates use of CO compositions to prevent or reduce intimal hyperplasia and/or arteriosclerosis in transplanted vasculature, e.g., individual blood vessels (e.g., vein or aortic transplants) or blood vessels that remain associated with a transplantable organ (e.g., kidney, liver, heart, or lung). Alternative or in addition to the *in situ* exposures described above, exposure of vasculature to CO compositions can occur *ex vivo*. For example, prior to transplanting individual blood vessels or an organ with its associated vasculature into a recipient patient, the vasculature may be exposed to an atmosphere comprising carbon monoxide gas, to a liquid carbon monoxide composition, e.g., a liquid perfusate, storage solution, or wash solution having carbon monoxide dissolved therein, or both.

Exposure of vasculature to gaseous CO compositions *ex vivo* can be performed in any chamber or area suitable for creating an atmosphere that includes appropriate levels of CO gas. Such chambers include, for example, incubators and chambers built for the purpose of accommodating an organ in a preservation solution. As another example, an appropriate chamber may be a chamber wherein only the gases fed into the chamber are present in the internal atmosphere, such that the concentration of carbon monoxide can be established and maintained at a given concentration and purity, e.g., where the chamber is airtight. For example, a CO<sub>2</sub> incubator may be used to expose vasculature to a carbon monoxide composition, wherein carbon monoxide gas is supplied in a continuous flow from a vessel that contains the gas.

Exposure of vasculature to liquid CO compositions *ex vivo* may be performed in any chamber or space having sufficient volume for submerging the vasculature,

completely or partially, in a liquid CO composition. Vasculature can also be exposed to such compositions by placing the vasculature in any suitable container, and causing a liquid CO composition to “wash over” or through the vasculature, such that the vasculature is exposed to a continuous flow of the CO composition. As yet another example, the vasculature may be submerged in a medium or solution that does not include CO, and placed in a chamber such that the medium or solution can be made into a CO composition via exposure to a CO-containing atmosphere as described herein. As still another example, the vasculature may be submerged in a liquid that does not include CO, and CO can be “bubbled” into the liquid.

### *Devices*

The present invention contemplates administering CO to a patient’s vasculature using a device that is capable of being used for both performing an angioplasty procedure and administering CO to a patient’s vasculature. CO can be administered through and/or by the instrument, or by a CO-delivering coating thereon, while angioplasty is being performed (e.g., immediately before, during, and/or immediately after angioplasty is performed). Such devices include devices used for balloon angioplasty (“balloon angioplasty devices”), laser angioplasty (“laser angioplasty devices”), and devices used for atherectomy (“atherectomy devices”), e.g., extraction atherectomy; directional atherectomy; rotational atherectomy; and stents. As used herein, an “angioplasty device” is any device that can be used to perform angioplasty on a patient.

Referring to Figs. 13A to 13D, examples of a catheter device with an inflatable member (e.g., a balloon) designed to administer CO (e.g., a liquid or gaseous CO composition) to a patient during angioplasty are shown. In Fig. 13A, the catheter 1303 is shown in position within a stenotic region 1302 of blood vessel 1301. The inflatable member 1304 is shown in the deflated state. The inflatable member includes at least one aperture 1305, through which CO can be administered to the vessel during the procedure. CO can be provided to the inflatable member (e.g., to inflate the inflatable member) from a reservoir (not shown) containing CO, e.g., a pharmaceutical composition comprising carbon monoxide. The device can optionally be guided to the intended site by a guide wire 1306.

In Fig. 13B, the catheter 1303 is shown with the inflatable member 1304 in an inflated state. CO can be administered through the aperture(s) 1305 to the vessel 1301. In one embodiment, the inflatable member is inflated with CO, or a mixture of gases including CO, such that an amount of the CO sufficient to treat intimal hyperplasia  
5 flows out of the aperture(s) 1305 and is delivered to the blood vessel 1301 during and/or after inflation of the inflatable member 1304.

Fig. 13C illustrates another embodiment of the catheter device, wherein the catheter 1303 includes at least one lumen 1307 for delivering CO to the blood vessel 1301 during the angioplasty procedure. Still another embodiment is shown in Fig. 13D,  
10 wherein a central lumen 1307 delivers CO to a plurality of sites in the blood vessel 1301. A reservoir containing CO (not shown) can be connected to the lumen 1307, such that a dose of CO is administered from the reservoir through the lumen 1307 to the blood vessel.

Alternatively or in addition, the inflatable member 1304 can be coated with a  
15 CO-releasing coating, e.g., a hydrogel containing a CO composition, such that CO is delivered to the stenotic region 1302, e.g., upon contact with the inflatable member 1304.

Referring to Figs. 14A to 14B, an example of a stent designed to administer CO to a patient is shown. The term “stent” is an art-recognized term and refers to a mesh  
20 tube, typically made of wire, used to maintain a blood vessel in an open position, e.g., a blood vessel that has recently been remodeled during angioplasty. In Fig. 14A, a stent 1402 is shown in a collapsed state. The stent covers a balloon catheter 1404, shown in Fig. 14A in a deflated state. In Fig. 14B, the stent 1402 and balloon catheter 1404 are shown in an expanded/inflated state. Upon inflation of the balloon catheter 1404, the  
25 stent 1402 expands, locks in place, and forms a scaffold as shown in Fig. 14B, thereby holding the blood vessel in an open position. In one embodiment of the present invention, the stent 1402 is coated with a CO-releasing coating, e.g., a hydrogel that releases CO, such that an amount of CO sufficient to treat intimal hyperplasia is delivered to the blood vessel for an appropriate amount of time, e.g., for as long as the  
30 stent remains in place.

Referring to Fig. 15, a catheter 1502 with two inflatable members 1504 is shown. The inflatable members 1504 can be used to isolate a stenotic region 1506, such that CO can be administered to the stenotic region 1506 between the inflatable

members 1504. The catheter 1502 is inserted into the blood vessel 1508 prior to inflation of the inflatable members 1504. The inflatable members 1504 are then inflated using an inflation/deflation tube 1510 housed within the catheter 1502. The inflatable members 1504 in their inflated state obstruct the flow of blood to the region of the blood vessel undergoing treatment. Intake ducts 1512 on the proximal end of the catheter allow blood to flow into and through the catheter 1502 to outlet ducts 1514 located on the distal end of the catheter. This allows the blood to continue flowing to the rest of the artery 1508 while the local site of the artery 1506 is treated. CO can be introduced to the isolated region through an administering supply tube 1516. The inflated inflatable members 1504 provide an isolated treatment area within which appropriate levels of CO can be administered to the vessel. In addition, fiber probes (not shown) can be secured to the casing of the catheter 1502, and the site can be exposed to electromagnetic radiation through the fiber probes. CO can be administered to the site before, during, and/or after treatment of the site with electromagnetic radiation.

Referring to Fig. 16, an example of an instrument capable of administering CO to a patient while performing atherectomy is shown. Atherectomy involves cutting away and removing plaque 1602 from blood vessel walls 1604. The catheter 1606 is positioned within the artery 1604. A flexible guide 1608 is used to move the instrument through the region of treatment 1610. Rotating cutting blades 1612 are then extended beyond the catheter 1606. The rotating cutting blades 1612 follow the flexible guide 1608 and cut through the plaque 1602. The rotating cutting blades 1612 draw the removed particles of plaque into and towards the proximal end of the catheter 1606. CO can be introduced to the treated region through an administering tube 1614 within the catheter 1606. An administering tube 1614 can be secured to the guide 1608. CO can be administered through the catheter 1606 through a least one pore 1616 on the distal end of the administering tube 1614. Alternatively or in addition to supplying CO through an administering tube 1614, ducts 1620 and 1622 can be housed within the walls of the cutting blades 1612. Carbon monoxide can be supplied through an outlet duct 1620. At the conclusion of treatment an inlet duct 1622 can remove the CO. CO can be administered before, during, and/or after removal of plaques.

In addition to the above, a skilled practitioner will appreciate that any device known in the art for performing angioplasty procedures can be modified to administer

CO to a patient's vasculature during use. Examples of such devices can be found, e.g., in U.S. Patent Nos. 6,409,716, 5,985,307, 6,508,787, 5,709,875 and 6,450,989.

Further, a skilled practitioner will recognize that any such devices can be coated with a CO-delivering agent, e.g., an oil, ointment or hydrogel, capable of releasing effective  
5 doses of CO, such that the CO is delivered to blood vessel upon contact with the instrument/coating.

#### Use of Hemoxygenase-1 and Other Compounds

10 Also contemplated by the present invention is the induction or expression of hemoxygenase-1 (HO-1) in conjunction with administration of carbon monoxide. HO-1 can be provided to a patient by inducing or expressing HO-1 in the patient, or by administering exogenous HO-1 directly to the patient. As used herein, the term "induce(d)" means to cause increased production of a protein, e.g., HO-1, in isolated  
15 cells or the cells of a tissue, organ or animal using the cells' own endogenous (e.g., non-recombinant) gene that encodes the protein.

HO-1 can be induced in a patient by any method known in the art. For example, production of HO-1 can be induced by hemin, by iron protoporphyrin, or by cobalt protoporphyrin. A variety of non-heme agents including heavy metals, cytokines,  
20 hormones, nitric oxide, COCl<sub>2</sub>, endotoxin and heat shock are also strong inducers of HO-1 expression (Otterbein *et al.*, Am. J. Physiol. Lung Cell Mol. Physiol. 279:L1029-L1037, 2000; Choi *et al.*, Am. J. Respir. Cell Mol. Biol. 15:9-19, 1996; Maines, Annu. Rev. Pharmacol. Toxicol. 37:517-554, 1997; and Tenhunen *et al.*, J. Lab. Clin. Med. 75:410-421, 1970). HO-1 is also highly induced by a variety of agents and conditions  
25 that create oxidative stress, including hydrogen peroxide, glutathione depletors, UV irradiation and hyperoxia (Choi *et al.*, Am. J. Respir. Cell Mol. Biol. 15: 9-19, 1996; Maines, Annu. Rev. Pharmacol. Toxicol. 37:517-554, 1997; and Keyse *et al.*, Proc. Natl. Acad. Sci. USA 86:99-103, 1989). A "pharmaceutical composition comprising an inducer of HO-1" means a pharmaceutical composition containing any agent capable  
30 of inducing HO-1 in a patient, e.g., any of the agents described above, e.g., hemin, iron protoporphyrin, and/or cobalt protoporphyrin.

HO-1 expression in a cell can be increased via gene transfer. As used herein, the term "express(ed)" means to cause increased production of a protein, e.g., HO-1 or



ferritin, in isolated cells or the cells of a tissue, organ or animal using an exogenously administered gene (e.g., a recombinant gene). The HO-1 or ferritin is preferably of the same species (e.g., human, mouse, rat, etc.) as the recipient, in order to minimize any immune reaction. Expression could be driven by a constitutive promoter (e.g.,  
5 cytomegalovirus promoters) or a tissue-specific promoter (e.g., milk whey promoter for mammary cells or albumin promoter for liver cells). An appropriate gene therapy vector (e.g., retrovirus, adenovirus, adeno associated virus (AAV), pox (e.g., vaccinia) virus, human immunodeficiency virus (HIV), the minute virus of mice, hepatitis B virus, influenza virus, Herpes Simplex Virus-1, and lentivirus) encoding HO-1 or  
10 ferritin would be administered to the patient orally, by inhalation, or by injection at a location appropriate for treatment intimal hyperplasia. Similarly, plasmid vectors encoding HO-1 or apo-ferritin can be administered, e.g., as naked DNA, in liposomes, or in microparticles.

Further, exogenous HO-1 protein can be directly administered to a patient by  
15 any method known in the art. Exogenous HO-1 can be directly administered in addition to, or as an alternative, to the induction or expression of HO-1 in the patient as described above. The HO-1 protein can be delivered to a patient, for example, in liposomes, and/or as a fusion protein, e.g., as a TAT-fusion protein (see, e.g., Becker-Hapak *et al.*, Methods 24:247–256, 2001).

20 Alternatively or in addition, any of the products of metabolism by HO-1, e.g., bilirubin, biliverdin, iron, and/or ferritin, can be administered to a patient in conjunction with, or instead of, carbon monoxide in order to prevent or treat intimal hyperplasia. Further, the present invention contemplates that iron-binding molecules other than ferritin, e.g., desferoxamine (DFO), iron dextran, and/or apoferritin, can be  
25 administered to the patient. Further still, the present invention contemplates that enzymes (e.g., biliverdin reductase) that catalyze the breakdown any of these products can be inhibited to create/enhance the desired effect.

The present invention contemplates that compounds that release CO into the body after administration of the compound (e.g., CO-releasing compounds), e.g.,  
30 dimanganese decacarbonyl, tricarbonyldichlororuthenium (II) dimer, and methylene chloride (e.g., at a dose of between 400 to 600 mg/kg, e.g., about 500mg/kg) can also be used in the methods of the present invention, as can carboxyhemoglobin and CO-donating hemoglobin substitutes, and .

Administration any of the above can be administered to a patient in any way, e.g., by oral, intravenous, or intraarterial administration. Any of the above compounds can be administered to the patient locally and/or systemically, and in any combination.

The invention is illustrated in part by the following examples, which are not to  
5 be taken as limiting the invention in any way.

Example 1. CO Suppresses Arteriosclerosis, Development of Intimal Hyperplasia and SMC Proliferation

10 **Animals.** Male (250-350g) Brown Norway rats (RT1<sup>a</sup>) were used as aortic graft donors and male (250-350g) Lewis rats (RT1<sup>i</sup>) as recipients. Dawley (400-450g) rats were used in the balloon injury model. Adult male C57BL/6, C57/S129, *p21*<sup>+</sup> and *p53*<sup>+</sup> null mice were purchased from Jackson Laboratory (Bar Harbor, ME). *mkk3*<sup>+/+</sup> null mice were generated as described Lu et al. (*EMBO*. 18:1845-1857 (1999)). The *inos*<sup>-/-</sup> and  
15 *enos*<sup>-/-</sup> mice were bred at the University of Pittsburgh.

**Aortic transplant model.** Aortic transplantation was performed as described in Shimizu et al. (*Nat Med*. 7:738-741 (2001)). Briefly, 3 to 4 cm of descending aorta was harvested from the donor and implanted between the renal arteries and the aortic  
20 bifurcation of the recipient. Both edges of the native abdominal aorta were ligated.

**Balloon injury model.** Balloon angioplasty was carried out as described in Murakami et al. (*Atherosclerosis* 157:361-368 (2001)). Briefly, a 2 Fr. arterial embolectomy catheter (Baxter, Chicago, IL) was inserted into the common carotid artery, and injury  
25 was created by inflating the balloon to 5 atmospheres of pressure for 5 minutes. The arteries were flushed and the external carotid artery was ligated, ensuring return of blood flow through the common and internal carotid arteries. Injury of the vessel wall and subsequent pathological analysis was made in a manner that was blinded to the treatment group.

30

**CO exposure.** CO was delivered to animals as described in Otterbein et al. (*Nat Med*. 6:422-428 (2000)). Graft donors and recipients were exposed to CO (250 ppm) for two days before transplantation and for 56 days immediately following transplantation. In

the balloon injury model, rats received either no pretreatment or were exposed to CO (250 ppm) for one hour prior to injury. Following surgery rats were housed in room air for two weeks.

5 **Cells.** Primary mouse and rat smooth muscle cells (SMC) were isolated and cultured as described in Laubach et al. (*Proc Natl Acad Sci USA* 92:10688-9 (1995)). Mouse SMC isolated from HO-1<sup>-/-</sup> mice were obtained as described in Duckers et al. (*Nat Med.* 7:693-698 (2001)).

10 **Cell treatment and reagents.** Guanylate cyclase inhibitor 1H(1,2,4) oxadiazolo(4,3-a)quinoxalin-1 (ODQ; Calbiochem-Novabiochem, San Diego, CA; 10–100  $\mu$ M) and p38 MAPK inhibitor pyridinyl imidazol SB203580 (Calbiochem; 5-20  $\mu$ M) were dissolved in DMSO. The cGMP analogue 8-bromo-cGMP sodium salt (8-Br-cGMP; Sigma-Aldrich, St. Louis, MO; 10–100  $\mu$ M) and the PKG inhibitor (10-100  $\mu$ M; Alexis  
15 Biochemicals) were dissolved in water.

**Cell counts and [<sup>3</sup>H] thymidine incorporation.** Rat and mouse SMC were isolated and cultured as described in Peyton et al. (*Blood* 99:4443-4448 (2002)). Proliferation assays were carried out as described in Petkova et al. (*J Biol. Chem.* 276:7932-7936  
20 (2001)). For [<sup>3</sup>H] thymidine incorporation studies, cells were serum-starved overnight and then stimulated with 10% serum containing 5  $\mu$ Ci/ml [<sup>3</sup>H] thymidine (New England Nuclear, Boston MA). [<sup>3</sup>H]thymidine incorporation was measured by scintillation spectroscopy and presented as mean counts/min/well.

25 **Histomorphometric analysis.** Aortic grafts and carotid arteries were harvested at 56 and 14 days respectively. Vessels were fixed, embedded, and serially sectioned (5  $\mu$ ) *in toto*. Every third slide was stained with Hematoxylin and Eosin (H&E) for histomorphometric analyses. In both models, one or two images per slide at a resolution of 1520 x 1080 pixels were captured at a magnification of 25X with a Zeiss  
30 microscope (Axioskop, Iowa City, Iowa), RT color SPOT (Diagnostic Instrument, Inc., Saint Joseph, MI) and Windows NT (Compaq Computer) using Adobe Photoshop version 5.5 software. Areas from eight to ten captured images were calculated using digital imaging software as number of pixels corresponding to those areas. Twenty-

four to forty-eight sections from each group were statistically analyzed with SPSS software version 10.

**Immunostaining and cell population histomorphometric analysis.** Grafts were

5 harvested 56 days after transplantation. Rat leukocyte populations were detected using anti-rat leukocyte common antigen (LCA, CD45; OX-1) (Serotec, Harlan Bioproducts, Indianapolis, IN); CD3 (G4.18), CD4 (OX-35), CD8 (OX-8), macrophage (CD68, ED-1), ICAM-1 (CD54; 1A29), and major histocompatibility class II (OX-6) were all obtained from Becton Dickinson Biosciences, (San Diego, CA). Anti-PAI-1 mAb was  
10 obtained from America Diagnostica (Greenwich, CT). Eight to ten images were captured from each transplanted aorta and analyzed as detailed above.

**Cell extracts and Western Blot Analysis.** Cellular protein extracts were

electrophoresed (10-12.5% polyacrylamide gels) and transferred onto nitrocellulose  
15 (BioRad, Hercules, CA). Total and phosphorylated forms of ERK, JNK and p38 MAPK as well as ATF-2 were detected using rabbit polyclonal antibodies (Cell Signaling Technologies, Beverly, MA). Anti  $\alpha$ -actin (Sigma; St. Louis, MO). p21<sup>Cip1</sup> was detected using a rabbit polyclonal antibody (Santa Cruz Biotech, Santa Cruz, CA). Primary antibodies were detected as described in supplementary methods.

20  
**Statistical Analysis.** The significance of difference was determined using analysis of variance (ANOVA).

**Nitric Oxide (NO) exposure.** Rats were exposed to 250 ppm or 500 ppm NO for 1

25 hour. NO gas (1% in N<sub>2</sub>) was mixed with air in the same exposure apparatus as used in the CO experiments. Concentrations in the chamber were monitored with an NO analyzer (Interscan). Following exposure, balloon angioplasty was carried out as described above. Control animals were exposed to air. The surgeon inflicting the balloon injury was blinded to the rats being manipulated. Analyses of carotid arteries  
30 was performed 2 weeks after the procedure as described above.

**Mouse arterial injury.** The dissection was similar to that described by Lindner et al. (*Circ Res.* 73:792-796 (1993)), and was performed using a 0.018 inch guide wire

(Cook, Bloomington, IN), inserted through an external carotid arteriotomy into the common carotid, rotated 360 degrees three times and removed a total of three consecutive times.

5 **cGMP immunoassays.** Cellular levels of cGMP were quantified using an EIA (Biomol, Plymouth Meeting, PA). SMC were incubated in the presence or absence of CO (250 ppm) and cell lysates were analyzed for cGMP content, as suggested by the vendor.

10 **Cell Counts.** Cells were seeded at  $5 \times 10^3$  cells/well and cultured overnight in high glucose DMEM containing 10% FCS, penicillin, and gentamicin (Life Technologies). Cells were serum starved for an additional 48 hours (0% serum) and where indicated exposed to CO (250 ppm for rat and mouse SMC) before induction of cell proliferation (10% FCS; Life Technology). Cells were counted daily using a Neubauer  
15 hemocytometer. Viability was assessed with trypan blue.

**Recombinant adenovirus.** Recombinant  $\beta$ -galactosidase adenovirus was obtained from the University of Texas Southwest Medical Center, Dallas, TX. Recombinant HO-1 adenovirus expressing the rat HO-1 cDNA has been described in Brouard et al. (*J*  
20 *Exp Med.* 192:1015-1026 (2000)). Rat SMC were infected with a multiplicity of infection (MOI) of 400 plaque forming units per cell (PFU/cell), as described in Brouard et al. (*Id.*).

**Flow Cytometry.** Rat aortic SMC were harvested by trypsin digestion (0.025%  
25 Trypsin/ 0.01%EDTA)(Life Technology), washed in phosphate buffered saline (PBS, pH 7.2) with 0.5% bovine serum albumin (BSA; Sigma-Aldrich Co), and incubated with Propidium iodide (1 $\mu$ g/ml, 1h, RT). Fluorescent labeling was evaluated using a FACsort equipped with Cell Quest Software (Becton Dickinson, Palo Alto, CA). Experiments were carried out in triplicate.

30

**Histomorphometric analyses.** In the transplant model, grafts were harvested 56 days after transplantation. Aortas were fixed in 10 % formalin, embedded in paraffin and serially sectioned (5  $\mu$ ) *in toto*. Ten samples from every three sections were placed per

slide in a total of about twenty-four to thirty slides. Every third slide was stained with Hematoxylin and Eosin (H&E) for histomorphometric analysis. In the balloon injury model, animals were euthanized 14 days following injury and arteries were collected for morphometric analysis. Rat carotid arteries were perfused and fixed *in situ* with  
 5 PBS and paraformaldehyde (2%). Vessels were fixed for 2 hours in 2% paraformaldehyde at 4°C and cryoprotected in 30% sucrose overnight at 4°C. Vessels were quick-frozen in 2-methylbutane and 7µm cryosections were cut.

**Primary Antibody Detection for Immunoblotting.** Primary antibodies were detected  
 10 using horseradish peroxidase conjugated anti-rabbit IgG secondary antibodies (Pierce, Rockford, IL, USA). Peroxidase was visualized using the Enhanced ChemiLuminescence assay (Amersham Life Science Inc., Arlington Heights, IL, USA), according to manufacturer's instructions and stored in the form of photoradiographs (BiomaxTMMS, Eastman Kodak, Rochester, NY). Where indicated, membranes were  
 15 stripped (62.5 mM Tris.HCl pH 6.8, 2% SDS and 100 mM β-mercaptoethanol, 30 minutes, 50 °C). Phosphorylated p38 were normalized to the total amount of p38, detected in the same membrane.

**Miscellaneous Reagents.** Mouse iNOS and eNOS were detected using rabbit anti-  
 20 mouse polyclonal antibodies against iNOS and eNOS (Becton Dickinson, Biosciences, San Diego, CA).

### **CO suppresses the development of transplant-associated arteriosclerosis.**

Figs. 1A-1I illustrate that CO treatment suppresses intimal hyperplasia normally  
 25 associated with chronic graft rejection. Figs. 1A-1F are photomicrographs of samples of various aortic grafts 56 days after transplantation. To generate these data, Brown Norway aortas were transplanted into Brown Norway rats (Figs 1A and 1D), Lewis rats exposed to air (Figs. 1B and 1E), and Lewis rats exposed to CO (250 ppm; Figs. 1C and 1F). Samples were harvested 56 days after transplantation and stained by a modified  
 30 elastic tissue-masson trichrome (elastic; Figs. 1A-1C) or by hematoxylin and eosin (H&E; Figs. 1D-1E). Elastic stainings are magnified 50x (Figs. 1A-1C) and H&E stainings are magnified 200x (Figs. 1D-1E). Samples shown are representative of 3-6 animals analyzed per group. Figs. 1G-1I are bar graphs illustrating the mean (±

standard deviation) relative areas corresponding to the intima and media regions, calculated from samples harvested from Brown Norway aortas transplanted into Brown Norway rats (Syng.; n=6), Lewis rats exposed to air (Allo.; n=6) or CO (250 ppm)(Allo. + CO; n=3). \*  $P < 0.001$  versus Allo.+CO.

5 Brown Norway aortic segments transplanted into Lewis rats developed arteriosclerotic lesions consistent with chronic graft rejection (Figs. 1B and 1E). The lesions appeared 20-30 days after transplantation but were significantly more pronounced by 50-60 days; all analyses were carried out 56 days following transplantation. The lesions were characterized by intimal hyperplasia, loss of medial  
10 SMC, and leukocyte accumulation in the adventitia (Figs. 1B and 1E). These characteristics were not observed in vessels of the recipient, and the lesions were not observed in syngeneic grafts (Figs. 1A and 1D). Intimal hyperplasia was significantly ( $p < 0.001$ ) inhibited ( $61.4 \pm 2.9\%$  reduction versus control) in aortas transplanted into recipients exposed to CO (250 ppm) immediately after transplantation (and for 56 days  
15 thereafter), as compared to those transplanted into air-exposed recipients (Figs. 1C, 1F, 1G, 1H, and 1I).

Figs. 2A-C are bar graphs illustrating that CO suppresses graft infiltration by activated leukocytes. To generate the data in Figs. 2A-2C, immunocytochemical analyses were performed on aortic grafts 56 days after transplantation. Brown Norway  
20 rat aortas were transplanted into Brown Norway rats (syngeneic), untreated Lewis rats (allogeneic) or Lewis rats exposed to CO (250-1000 ppm). Samples were harvested 56 days after transplantation. Fig. 2A illustrates the mean ( $\pm$  standard deviation (n=3-6)) number of nuclei in the adventitia from Brown Norway aortas transplanted into Brown Norway recipients (Syngeneic), untreated Lewis recipients (Allogeneic), and Lewis  
25 recipients exposed to various concentrations of CO (CO 250 ppm, CO 500 ppm, and CO 750-1000 ppm) (\* =  $P < 0.001$  versus Allo.). Fig. 2B illustrates the mean ( $\pm$  standard deviation (n=6)) number of CD45 (\* $P < 0.002$  versus Allo.), CD68 (M $\phi$ /ED1; \* $P < 0.001$  versus Allo.), MHC II, and CD54 (ICAM-1) positive cells (\* $P < 0.001$  versus Allo.) in the adventitia from Brown Norway rat aortas transplanted into Brown Norway  
30 rat recipients (Syng.), untreated Lewis rat recipients (Allo.), and Lewis rat recipients exposed to CO (Allo. + CO). Fig. 2C illustrates the mean ( $\pm$  standard deviation (n=6)) number of CD3, CD4, and CD8 positive cells (\* $P < 0.02, 0.001, 0.096$  respectively versus Allo.) in the adventitia from Brown Norway aortas transplanted into Brown

Norway recipients (Syng.), untreated Lewis recipients (Allo.), and Lewis recipients exposed to CO (CO 250 ppm).

Accumulation of leukocytes in the adventitia of transplanted aortas was inhibited in CO-exposed recipients (see Figs. 2A-2C). Leukocyte accumulation was not observed in syngeneic grafts. The ability of CO to suppress graft infiltration by activated leukocytes (CD45<sup>+</sup>) was dose dependent with increasing levels of CO (250-1000 ppm) resulting in decreased leukocyte infiltration; a maximal effect was observed at 700 to 1000 ppm of CO ( $52 \pm 20$  % inhibition versus air treated controls Fig. 2A). CO significantly suppressed the accumulation of CD45<sup>+</sup>/CD68<sup>+</sup> monocyte/macrophages (M $\phi$ ) ( $65 \pm 24$  % inhibition versus air treated controls) as well as CD45<sup>+</sup>/CD3<sup>+</sup> T cells ( $57 \pm 22$  % inhibition versus air treated controls), including both CD4<sup>+</sup> ("helper") and CD8<sup>+</sup> ("cytotoxic") cells (Fig. 2C). CO also inhibited expression of pro-inflammatory genes associated with M $\phi$  activation including the major histocompatibility class II (MHC II) antigens and the intracellular adhesion molecule 1 (CD54/ICAM-1) (Fig. 2B).

#### **CO suppresses development of intimal hyperplasia after balloon injury.**

Figs 3A-3G illustrate that CO suppresses the development of vascular lesions associated with balloon injury. Figs. 3A-3D are photomicrographs (10x magnification) of immunocytochemically stained carotid arteries analyzed 14 days after balloon angioplasty. To generate the data in Figs. 3A-3D, rats were exposed to room air (Figs. 3A and 3C) or to CO (1 hour; 250 ppm; Figs. 3B and 3D) prior to balloon injury. All animals were exposed to room air following balloon injury. Two weeks after balloon injury, samples were stained with hemotoxylin and eosin (H&E). Samples from room air (Figs. 3A and 3C) and CO pretreated rats (Figs. 3B and 3D) are shown. Fig. 3E, 3F, and 3G are bar graphs illustrating the mean ( $\pm$  standard deviation ( $n=8$ ; \*  $P<0.001$  versus control)) relative areas of the intima and media regions of samples analyzed in Figs. 3A-3D.

Rat carotid arteries developed intimal hyperplasia 14 days after balloon injury (Figs. 3A and 3C; and Figs. 3E-3G). Intimal hyperplasia in rats exposed to CO (250 ppm) for one hour prior to balloon injury (after which CO exposure was discontinued) was suppressed by  $74 \pm 8$  % as compared to control animals exposed to air ( $n=8-10$ ;  $p<0.001$ ) (Figs. 3B and 3D and Figs. 3E-3G).



### CO suppresses SMC proliferation.

Figs 4A-4F illustrate that CO blocks SMC proliferation and that p21<sup>Cip1</sup> is involved in the anti-proliferative effect of CO *in vitro*. Fig. 4A is a line graph illustrating proliferation of rat SMC that were non-transduced (○; Medium), or transduced with Lac.Z (□; LacZ Rec. Ad.) or HO-1 (●; HO-1 rec. Ad.) recombinant adenovirus. Results shown are mean ± standard deviation of n=3 wells per group (\*  $P < 0.001$  versus LacZ and non-transduced). Fig. 4B is a line graph illustrating proliferation of rat SMC growth in the presence or absence of CO (●; 1000 ppm). Results shown are mean ± standard deviation (n=3 wells per group;  $P < 0.001$  versus air, □). Fig. 4C is a bar graph illustrating proliferation of SMC isolated from wild type (WT) or HO-1 deficient (*ho-1*<sup>-/-</sup>) mice in the presence and absence of CO (250 ppm) (n=6 wells/group; #  $P < 0.006$  versus air, \*  $P < 0.001$ ). Fig. 4D is a Western blot illustrating p21 and β-actin protein expression in mouse SMC following exposure to CO (250 ppm). Fig. 4E is a bar graph illustrating proliferation of mouse SMC isolated from wild type (wt), p21<sup>Cip1</sup> (*p21*<sup>-/-</sup>) or p53 (*p53*<sup>-/-</sup>) deficient mice. Gray bars indicate cells exposed to room air and black bars indicate cells exposed to CO (250 ppm). Results shown are the mean ± standard deviation (n=3 \*  $P < 0.001$  versus air) in one out of 6 independent experiments. Fig. 4F is a bar graph illustrating that endogenous expression of p21<sup>Cip1</sup> plays a critical role in controlling the extent of intimal hyperplasia following arterial injury in mice. Wild type (C57/Bl6/S129) or *p21*<sup>-/-</sup> mice were exposed to room air or CO (1 hour; 250 ppm) before carotid artery injury and exposed to room air thereafter. Samples were harvested and analyzed two weeks after injury. Mean ± standard deviation (n=4) of the ratio between the relative area of the intima and media is expressed in arbitrary units (\*  $P < 0.001$  versus air).

Figs. 7A-7B further illustrate that CO blocks SMC proliferation. Fig. 7A is a cell cycle analysis of rat aortic SMC in standard incubation (Air) versus CO (250 ppm) after 24 hours of treatment. Results shown are representative of 3 independent experiments. Fig. 7B is a line graph illustrating SMC proliferation in the presence (■; CO, 250 ppm) or absence (□; air) of CO for 6 days. SMC were serum stimulated on day 3 of the experiment. Proliferation increased in CO-treated SMC after CO exposure was discontinued on day 6. Results shown are representative of 3 independent experiments, each performed in triplicate (\*  $P < 0.01$  vs Air).

Fig. 8 is a bar graph illustrating that CO blocks SMC proliferation from wild type (wt) and p53<sup>-/-</sup> mice but not from p21<sup>-/-</sup> mice. The figure presents the results of a [<sup>3</sup>H]thymidine incorporation assay used to assess cellular proliferation (counts per minute; cpm) in wild type (wt), p21<sup>-/-</sup>, and p53<sup>-/-</sup> mouse SMCs exposed to air (gray bars) or to CO (250 ppm; black bars) for 24 hours. Results shown are the mean ± standard deviation (n=3; \*P<0.05 versus air).

Figs. 9A-9G illustrate that CO suppresses the development of vascular lesions associated with wire injury in *wild type* (C57/Bl6/S129) and *p21*<sup>-/-</sup> mice. Figs. 9A-9D are photomicrographs (20x magnification) of immunocytochemically stained carotid arteries 14 days following wire injury. Mice were exposed to room air (Figs. 9A and 9C) or CO (1 hour; 250 ppm; Figs. 9B and 9D) prior to wire injury. All animals were exposed to room air following injury. Two weeks after wire injury, samples were stained with hemotoxylin and eosin (H&E). Samples from wild type (Figs. 9A and 9B) and *p21*<sup>-/-</sup> (Figs. 9C and 9D) mice are shown. Figs. 9E, 9F, and 9G are bar graphs illustrating the Mean (± standard deviation (n=4 \* P<0.001 versus control)) relative areas corresponding to the intima and media regions, as well as intima:media ratios, from the photomicrographs shown in Figs. 9A-9D.

#### *CO suppresses SMC proliferation in vitro*

An in vitro system was used to evaluate SMC growth in the presence or absence of CO to delineate the mechanism by which CO inhibited intimal hyperplasia. Serum starved SMC proliferated upon re-addition of serum to culture medium (Fig. 7B); control SMC not exposed to serum exhibited minimal proliferation during the five days of the experiment. Expression of a HO-1 recombinant adenovirus or exposure to CO suppressed SMC proliferation (Figs. 4A and 4B). In a similar system, “scavenging” of CO by hemoglobin suppressed the anti-proliferative effect of HO-1, suggesting that CO generated by HO-1 likely accounts for the anti-proliferative effect of HO-1. Cell cycle analysis revealed that SMC treated with CO accumulated in the G0/G1 phase (Fig. 7A). SMC from mice that lack HO-1 (*ho-1*<sup>-/-</sup>) proliferated significantly more rapidly when exposed to serum than did SMC from wild type mice (Fig. 4C), indicating that endogenous HO-1 expression in SMC exposed to serum suppresses smooth muscle cell proliferation. CO significantly inhibited proliferation of SMC from *ho-1*<sup>-/-</sup> mice, suggesting that CO accounts in large measure for the anti-proliferative action of HO-1.

Inhibition of SMC proliferation was not associated with cell death as assessed by trypan blue and propidium iodide exclusion analyses. The anti-proliferative effects of CO were reversible, as cessation of CO exposure allowed SMC to begin to proliferate again (Fig. 7B).

5

*The in vitro anti-proliferative effect of CO depends on p21<sup>Cip1</sup>.*

SMC exposed to CO up-regulated p21<sup>Cip1</sup> protein expression (Fig. 4D), similar to SMC that overexpressed HO-1. This effect was transitory in that p21<sup>Cip1</sup> expression increased significantly by 4 hours, was maximal by 16 hours and returned to basal  
 10 levels at 24 hours after CO exposure (Fig. 4D). Proliferation of SMC from p21<sup>Cip1</sup> deficient mice (*p21<sup>-/-</sup>*) was not suppressed by CO (Fig. 4E), indicating that p21<sup>Cip1</sup> expression is required for the anti-proliferative effect of CO. Despite the established role of p53 in regulation of p21<sup>Cip1</sup> expression, CO induced p21<sup>Cip1</sup> expression and inhibited proliferation of SMC derived from *p53<sup>-/-</sup>* or from wild type mice to a similar  
 15 extent (Fig. 4E and Fig. 8). Thus, the anti-proliferative effect of CO in vitro is dependent on p21<sup>Cip1</sup> expression, which does not involve p53.

*Involvement of p21<sup>Cip1</sup> in the in vivo anti-proliferative effect of CO*

p21<sup>Cip1</sup> is expressed following vascular wall injury, likely functioning to  
 20 regulate SMC proliferation and the development of intimal hyperplasia. The role of endogenous p21<sup>Cip1</sup> expression on development of intimal hyperplasia following arterial injury in mice was investigated. Intimal hyperplasia was three times more pronounced in air treated *p21<sup>-/-</sup>* mice than in *wild-type* mice ( $n=4$ ;  $314 \pm 41.8\%$ ,  $p<0.001$ ), showing that endogenous expression of p21<sup>Cip1</sup> plays a critical role in  
 25 controlling the extent of intimal hyperplasia following arterial injury in mice (Fig. 4F). In contrast, one hour of CO (250 ppm) pre-treatment suppressed intimal hyperplasia in both wild-type (C57/S129) and *p21<sup>-/-</sup>* (C57/S129) mice by  $80.9 \pm 7.2\%$  ( $n=4$ ,  $p<0.001$ ) and  $86.2 \pm 14\%$  ( $n=4$ ,  $p<0.001$ ), respectively, versus air treated controls (Fig. 4F; Figs. 9A-9G). Thus, in this in vivo mouse model, CO suppresses intimal hyperplasia via a  
 30 mechanism that is not dependent on the expression of p21<sup>Cip1</sup>.

*The anti-proliferative effect of CO requires activation of guanylate cyclase and generation of cGMP, and is exerted via activation of p38 MAPK.*

Figs. 5A-5G illustrate that CO blocks SMC proliferation via generation of cGMP and activation of p38 MAPK. Fig. 5A is a bar graph illustrating the mean ( $\pm$  standard deviation ( $n=3$ )) cellular cGMP content in mouse SMC exposed to air or CO (250 ppm for 8 h or 16h). Fig. 5B is a bar graph illustrating the results of a

5  $[^3\text{H}]$ thymidine incorporation assay used to assess cellular proliferation (counts per minute; cpm) in mouse SMC exposed to CO (250 ppm) in the presence or absence of the guanylate cyclase inhibitor ODQ. Results shown are the mean  $\pm$  standard deviation ( $n=3$ ;  $*P<0.05$  versus air and CO/ODQ). Fig. 5C is a picture of a Western blot of  $p21^{\text{Cip1}}$  mouse SMC exposed to the cGMP analogue 8Br-cGMP. Membranes were

10 subsequently probed for  $\beta$ -actin to assure equal loading. Results shown are representative of 3 independent experiments. Fig. 5D is a bar graph illustrating  $[^3\text{H}]$ thymidine incorporation of SMC isolated from wild type (wt) and  $p21^{\text{Cip1}}$  ( $p21^{-/-}$ ) deficient mice in the presence and absence of the cGMP analogue 8Br-cGMP. Results shown are the mean  $\pm$  standard deviation ( $n=4$ ;  $*P<0.05$  versus air and 8Br-cGMP).

15 Fig. 5E is a composite picture of a Western blot of phosphorylated p38 MAPK (p-p38), ATF-2 (p-ATF-2), JNK (p-JNK) and ERK (p-ERK) of SMC exposed to CO (250 ppm). Membranes were subsequently probed with an antibody against total p38 MAPK, ATF-2, JNK and ERK to assure equal loading. Blots are representative of 3 independent experiments. Fig. 5F is a bar graph illustrating  $[^3\text{H}]$ thymidine incorporation in mouse

20 SMC exposed to CO (250 ppm) in the presence and absence of the p38 MAPK inhibitor SB203580. Results shown are the mean  $\pm$  standard deviation from 4 independent experiments ( $p<0.005$ ; versus air and CO/SB treated cells). Fig. 5G is a composite picture of a Western blot of  $p21^{\text{Cip1}}$  from mouse SMC exposed to CO (250 ppm) in the presence and absence of the p38 MAPK inhibitor SB203580 or DMSO,

25 used as a vehicle. The same membrane was probed with an antibody against  $\beta$ -actin to assure equal loading. Results shown are representative of 3 independent experiments.

Figs. 6A-6B illustrate that CO activates p38 MAPK through a mechanism that requires the generation of cGMP. Fig. 6A is a composite picture of a Western blot of phosphorylated p38 MAPK from mouse SMC exposed to the cGMP analogue

30 8Br-cGMP. Membranes were subsequently probed with an antibody against total p38 to assure equal loading. The composite blot shown in Fig. 6A is representative of 3 independent experiments. Fig. 6B is a bar graph illustrating  $[^3\text{H}]$ thymidine incorporation in mouse SMC exposed to CO (250 ppm) in the presence and absence of

the cGMP analog 8-Br-cGMP. Results shown are the mean  $\pm$  standard deviation from 4 independent experiments.

Fig. 10 is a bar graph illustrating that CO does not suppress proliferation in SMC from *p21*<sup>-/-</sup> mice. The bar graph presents the results of a [<sup>3</sup>H]thymidine incorporation assay to assess cellular proliferation (counts per minute; cpm) in SMC derived from *p21*<sup>-/-</sup> mice treated with CO (250 ppm) in the presence and absence of the p38 MAPK inhibitor SB203580 (SB).

Exposure of SMC to CO increased intracellular cGMP levels (Fig. 5A). The ability of CO to suppress SMC proliferation and to up-regulate p21<sup>Cip1</sup> expression was impaired under inhibition of guanylate cyclase activity by 1H(1,2,4) Oxadiazolo(4,3-a) Quinoxalin-1 (ODQ) (Fig. 5B). The non-degradable cGMP analogue 8-Bromoguanosine 3'-5'-cyclic monophosphate sodium salt (8-Br-cGMP) suppressed SMC proliferation (Fig. 5D) and increased expression of p21<sup>Cip1</sup> comparably to CO (Fig. 5C). Suppression of proliferation by 8-Br-cGMP was impaired in SMC derived from *p21*<sup>-/-</sup> mice (Fig. 5D). It thus appears that the anti-proliferative effect of CO is mediated via activation of guanylate cyclase, accumulation of cGMP and expression/activation of p21<sup>Cip1</sup>. Activation of cGMP dependent kinases (PKG  $\alpha$  and  $\beta$ ) seems to be required for CO to suppress SMC proliferation since an inhibitor of PKG abrogated the anti-proliferative effect of CO.

Whether the anti-proliferative effect of CO in SMC involved the activation of the p38 MAPK signal transduction pathway was investigated. CO activated p38 MAPK in SMC (Fig. 5E), as it does in endothelial cells and monocytes/macrophages. p38 MAPK phosphorylation/activation peaked four hours after exposure to CO and returned to basal levels thereafter (Fig. 5E). Exposure of SMC to CO was also associated with the activation of ATF-2, a transcription factor most often activated through the p38 MAPK signal transduction pathway (Fig. 5E). Inhibition of p38 MAPK activation by the pyridinyl imidazol SB203580, a selective inhibitor of the p38  $\alpha$  and  $\beta$  isoforms, blocked the ability of CO to up-regulate expression of p21<sup>Cip1</sup> (Fig. 5G) and suppressed the anti-proliferative effect of CO (Fig. 5F). Additionally, CO did not inhibit proliferation in cells isolated from mice deficient in mitogen activated protein kinase kinase 3 (*mkk3*<sup>-/-</sup>), the upstream kinase that activates p38 $\alpha$  and p38 $\beta$ . SB203580 did not modulate the effects of CO on proliferation of SMC from *p21*<sup>-/-</sup>

mice (Fig. 10). These data indicate that p38 MAPK activation is critical for upregulation of p21<sup>Cip1</sup> and inhibition of SMC proliferation by CO. CO did not modulate activation of extra-cellular regulated kinases 1 and 2 (ERK-1 and -2) (Fig. 5E), indicating that this signal transduction pathway is not involved in the anti-proliferative effect of CO. CO induced activation of jun-activated kinases 1 and 2 (JNK-1 and -2) (Fig. 5E).

Given that CO induces the generation of cGMP (Fig. 5A) and activation of p38 MAPK (Fig. 5E) in SMC, the interrelationship between these two signal transduction pathways was investigated. Activation of p38 MAPK by CO was abolished when the generation of cGMP was blocked by ODQ. Exposure of SMC to 8-bromo-cGMP activated p38 MAPK (Fig. 6A) and the anti-proliferative effect of 8Br-cGMP was abrogated in the presence of SB203580 (Fig. 6B). Consistent with these findings, the ability of 8Br-cGMP to up-regulate the expression of p21<sup>Cip1</sup> was suppressed by SB203580.

*The anti-proliferative effect of CO does not require expression of nitric oxide synthases.*

Figs. 11A-11B illustrate that NO is not involved with the anti-proliferative effect of CO. Fig. 11A is a bar graph illustrating [<sup>3</sup>H]thymidine incorporation in mouse SMC isolated from wild type (wt) and *enos*<sup>-/-</sup> and *inos*<sup>-/-</sup> deficient mice in the presence and absence of CO (250 ppm). Results shown are the mean ± standard deviation (n=6-8, \* *P*<0.001 versus wt). Fig. 11B is a bar graph illustrating the mean intimal and media areas of carotid arteries from Sprague-Dawley rats exposed to room air (white bars) or NO (Black bars; 1 hour; 250 ppm) before balloon injury of the carotid artery. All animals were exposed to room air following injury. Two weeks after injury carotid arteries were removed, sectioned and stained with hematoxylin and eosin (H&E). Areas corresponding to the intimal and media regions were calculated. Results are the mean ± standard deviation from representative 40 sections taken from 3 rats per treatment group.

SMC exposed to CO (250 or 10,000 ppm) for varying amounts of time showed no induction of either NOS isoform by western blotting. SMC from mice deficient for the constitutive/endothelial isoform of nitric oxide synthase (eNOS/NOS-3; *nos-3*<sup>-/-</sup>) or the inducible isoform (iNOS/NOS-2; *nos-2*<sup>-/-</sup>) showed a significantly greater uptake of

thymidine when exposed to serum as compared to SMC derived from wild type mice (Fig. 11A). Exposure to CO significantly inhibited proliferation of SMC derived from wild type, *nos-2<sup>-/-</sup>* or *nos-3<sup>-/-</sup>* mice ( $51 \pm 12.9\%$  and  $51 \pm 25\%$  and  $54 \pm 11\%$  inhibition respectively;  $p < 0.001$  versus air treated controls) (Fig. 11A). These data indicate that the anti-proliferative effect of CO can occur in the absence of iNOS or eNOS. Similarly, under similar conditions to the ones used for CO (250 ppm; one hour pre-treatment), NO did not modulate intimal thickening triggered by balloon injury. NO administered at 500 ppm was lethal.

*CO does not inhibit the expression of the plasminogen activator inhibitor type 1 (PAI-1) in SMC.*

Figs. 12A, 12B and 12C illustrate that CO increases PAI-1 protein expression levels. Fig. 12A is a composite picture of a Western blot analysis for PAI-1 in SMC treated with and without CO (250 ppm) for 24 or 48 hours. Whole cell lysates from rat liver homogenates treated with and without endotoxin (LPS) were used as controls.  $\alpha$ -actin was used to assay protein loading. Fig. 12B is a composite picture of a Western blot analysis for PAI-1 in untransplanted (control), transplanted (Allo. + Air), and CO-treated transplanted (Allo. + CO) aortas after 56 days. Fig. 12C is the Commassie blue-stained polyacrylamide gel used to create the Western blot of Fig. 12B, and illustrates that the same amount of protein is loaded in each lane.

CO suppresses expression of PAI-1 in M $\phi$ , which is key to the protective effect of CO in preventing lung ischemia reperfusion injury in mice. Exposure of SMC to serum did not alter expression of PAI-1 by western blot (Fig. 12A). CO treatment slightly increased PAI-1 protein, suggesting that the anti-proliferative effect of CO does not involve down-regulation of PAI-1. Similarly, PAI-1 protein expression in allogeneic aortas transplanted under CO treatment was similar to that of allogeneic aortas transplanted in the absence of CO as tested by immunohistology and Western blot (Fig. 12B). This suggests that the ability of CO to modulate vascular injury associated with chronic graft rejection might not be directly linked to the expression of PAI-1.

CO is generated physiologically in most cell types through the catabolism of heme by

enzymes of the heme oxygenase family. Expression of the inducible enzyme, HO-1, is a protective response to injury that limits the deleterious effects associated with inflammatory reactions. The protective effects of HO-1 are wide-ranging, including inhibition of the development of atherogenesis and intimal hyperplasia, and can in many instances be mimicked by CO. The present studies demonstrate that CO possesses direct vasoprotective properties. Continuous exposure to low concentration of CO (250 ppm) suppresses development of intimal hyperplasia and graft infiltration by activated leukocytes (Figs. 1A-1I and 2A-2C) associated with transplant arteriosclerosis (Fig. 1A-1I). Exposure to CO (250 ppm) for just one hour prior to injury suppresses the intimal hyperplasia associated with carotid artery angioplasty injury in rats (Figs. 3A-3G).

The physiologic relevance of the anti-proliferative effect of HO-1 in SMC, originally described in pulmonary epithelial cells, is supported by the observation that SMC from HO-1 deficient mice proliferate more rapidly *in vitro* and *in vivo* than wild type SMC. The present data demonstrate that CO suppresses SMC proliferation in a manner similar to HO-1.

Generation of cGMP and the expression of p21<sup>Cip1</sup> are essential for the effects of CO, and are interrelated. The ability of CO to up-regulate p21<sup>Cip1</sup> expression and suppress SMC proliferation is dependent on activation of guanylate cyclase (Figs. 5A-5G). CO up-regulates p21<sup>Cip1</sup> (Figs. 4A-4F) and the anti-proliferative effect of CO is dependent on the expression of p21<sup>Cip1</sup> as this effect is abrogated in p21<sup>Cip1</sup><sup>-/-</sup> SMC (Figs. 6A-6B). The ability of 8-Br-cGMP to suppress SMC proliferation was impaired in SMC derived from p21<sup>Cip1</sup> deficient mice (Figs. 5A-5G), suggesting that cGMP suppresses SMC proliferation *in vitro* via the up-regulation of p21<sup>Cip1</sup>.

The individual contribution of cGMP and p38 MAPK to the effects of CO seems to be cell type specific. The present data demonstrate that the anti-proliferative effect of CO in SMC is dependent on both signal transduction pathways (Figs. 5A-5G). CO requires cGMP for activation of p38 MAPK, which is needed for CO to up-regulate p21<sup>Cip1</sup> and suppress SMC proliferation. It is suggested that CO, like NO, activates p38 MAPK via cGMP and activation of cGMP dependent protein kinases, consistent with the observation that inhibition of PKG  $\alpha$  and/or  $\beta$  suppresses the anti-proliferative effect of CO. The present data suggest that the anti-proliferative effect of CO is distinct from



and can act independently of NO. It should be noted that the link between cGMP, p38 MAPK and p21<sup>Cip1</sup> has not been reported in cells exposed to HO-1 or CO.

SMC express p21<sup>Cip1</sup> upon vascular injury and recombinant adenovirus mediated p21<sup>Cip1</sup> expression in SMC suppresses intimal hyperplasia following vascular injury. The present data show that physiological expression of p21<sup>Cip1</sup> is involved in intimal hyperplasia: following arterial injury, intimal hyperplasia in *p21*<sup>-/-</sup> mice is three times higher as wild type controls (Fig. 4F), strongly supporting the notion that CO induction of p21Cip1 expression in SMC (Fig. 5D) contributes to suppress intimal hyperplasia following vascular injury.

*p21*<sup>-/-</sup> mice were used to assess the role of p21<sup>Cip1</sup> expression on the ability of CO to suppress intimal hyperplasia following arterial injury, *p21*<sup>-/-</sup> mice. One hour of CO pretreatment was sufficient to suppress by more than 80% the development of intimal hyperplasia in *p21*<sup>-/-</sup> mice or wild-type mice, as compared with their respective air-treated controls (Fig. 4F). One interpretation of these data is that the ability of CO to suppress neointimal proliferation in vivo acts independently of p21<sup>Cip1</sup> in SMC. In mice, in contrast with rats, there is a significant inflammatory/thrombotic process that presumably leads to intimal proliferation. Given the potent anti-inflammatory effects of CO, it also seems possible that CO suppresses intimal hyperplasia in mice by inhibiting inflammation, a process that is almost certainly independent of p21Cip1.

Given the known suppression of PAI-1 by CO in monocyte-macrophages and the importance of PAI-1 in the pathogenesis of intimal hyperplasia following vascular injury in some studies, whether a similar suppression of PAI-1 occurred in the present system was investigated. No decrease in the level of PAI-1 protein expression at 56 days after transplantation was observed (Fig. 12B).

#### Example 2. Protocols for the Treatment of Patients During Angioplasty and Transplantation Procedures.

The following example illustrates protocols for treating patients during angioplasty procedures and for treating a donor, organ, and/or recipient with carbon monoxide during a transplantation procedure. Any one or more of the following procedures may be used in a given transplantation procedure.

## Angioplasty

CO can be administered systemically or locally to a patient prior to, during, and/or after an angioplasty procedure is performed in the patient. Treatment can be administered at doses varying from 10 ppm to 1000 ppm (e.g., about 100 ppm to about 5 800 ppm, about 150 ppm to about 600 ppm (e.g., about 150 ppm), or about 200 ppm to about 500 ppm (e.g., about 250 ppm or about 500 ppm)). For example, CO can be administered to the patient, intermittently or continuously, starting 0 to 20 days before the procedure is performed, e.g., starting at least about 30 minutes, e.g., about 1, 2, 3, 5, 7, or 10 hours, or about 1, 2, 4, 6, 8, 10, 12, 14, 18, or 20 days, or greater than 20 days, 10 before the procedure. Alternatively or in addition, CO can be administered to the patient during the procedure, e.g., through an instrument used to perform the angioplasty and/or by inhalation. Alternatively or in addition, CO can be administered to the patient after the procedure, e.g., starting immediately after completion of the procedure, and continuing for about 1, 2, 3, 5, 7, or 10 hours, or about 1, 2, 5, 8, 10, 20, 15 30, 50, or 60 days, or indefinitely, after the completion of the procedure.

## Transplantation

### *Treatment of a Donor*

Prior to harvesting an organ or tissue, the donor can be treated with inhaled 20 carbon monoxide (250 ppm) for one hour. Treatment can be administered at doses varying from 10 ppm to 1000 ppm for times varying from one hour to six hours, or for the entire period from the moment when it becomes possible to treat a brain-dead (cadaver) donor to the time the organ is removed. Treatment should start as soon as possible following the declaration that brain death is present. In some applications, it 25 may be desirable to begin treatment before brain death.

For non-human animals (e.g., pigs) to be used as xenotransplantation donors, the live animal can be treated with relatively high levels of inhaled carbon monoxide, as desired, so long as the carboxyhemoglobin so produced does not compromise the viability and function of the organ to be transplanted. For example, one could use 30 levels greater than 500 ppm (e.g., 1000 ppm or higher, and up to 10,000 ppm, particularly for brief times).

*Treatment of the organ in situ*

Before an organ is harvested from a donor, it can be flushed with a solution, e.g., a buffer or medium, without red blood cells while it is still in the donor. The intent is to flush the organ with a solution saturated with carbon monoxide and  
5 maintained in a carbon monoxide atmosphere so that the carbon monoxide content remains at saturation. Flushing can take place for a time period of at least 10 minutes, e.g., 1 hour, several hours, or longer. The solution should ideally deliver the highest concentration of carbon monoxide possible to the vasculature of the organ.

*Treatment of an Organ or Tissue*

10 The organ or tissue can be preserved in a medium that includes carbon monoxide from the time it is removed from the donor to the time it is transplanted to the recipient. This can be performed by maintaining the organ or tissue in the medium comprising CO, or by perfusing it with such a medium. Since this occurs ex vivo  
15 rather than in an animal, very high concentrations of CO gas can be used (e.g., 10,000 ppm) to keep the medium saturated with CO.

*Treatment of a Recipient*

The recipient can be treated with carbon monoxide. Treatment can begin on  
20 any day before the transplantation procedure, e.g., on the day of the transplantation procedure at least one hour before surgery begins. Alternatively, it could begin at least 30 minutes before re-perfusion of the organ in the recipient. It can be continued for at least 30 minutes, e.g., 1 hour. Carbon monoxide doses between 10 ppm and 3000 ppm can be delivered for varying times, e.g., minutes or hours, and can be administered on  
25 the day of and on days following transplantation. For example, a recipient can inhale a concentration of carbon monoxide, e.g., 3000 ppm, for three consecutive 10 second breath holds. Alternatively, the recipient can inhale, say 200 ppm for an extended time, such as 20 days. Carboxyhemoglobin concentrations can be utilized as a guide for appropriate administration of carbon monoxide to a patient. Usually, treatments for  
30 recipients should not raise carboxyhemoglobin levels above those considered to pose an acceptable risk for a patient in need of a transplant.

A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from

the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.

**WHAT IS CLAIMED IS:**

1. A method of performing angioplasty in a patient, the method comprising:
  - (a) performing angioplasty on the patient; and
  - (b) before, during, or after (a), administering to the patient a pharmaceutical
- 5 composition comprising an amount of carbon monoxide effective to treat intimal hyperplasia in the patient.
2. The method of claim 1, wherein the angioplasty comprises balloon angioplasty.
- 10 3. The method of claim 1, wherein the angioplasty comprises laser angioplasty.
4. The method of claim 1, wherein the angioplasty comprises directional atherectomy.
5. The method of claim 1, wherein the angioplasty comprises rotational atherectomy.
- 15 6. The method of claim 1, wherein the angioplasty comprises extraction atherectomy.
7. The method of claim 1, wherein the angioplasty comprises a stenting procedure.
- 20 8. The method of claim 1, wherein the angioplasty comprises balloon angioplasty and a stenting procedure.
9. A method of treating restenosis in a patient, the method comprising:
  - (a) providing a vessel containing a pressurized gas comprising carbon monoxide
- 25 gas;
- (b) identifying a patient suffering from or at risk for restenosis;
- (c) releasing the pressurized gas from the vessel, to form an atmosphere comprising carbon monoxide gas; and
- (d) exposing the patient to the atmosphere, wherein the amount of carbon monoxide in the atmosphere is sufficient to treat restenosis in the patient.

10. A vessel comprising medical grade compressed carbon monoxide gas, the vessel bearing a label indicating that the gas can be used to reduce restenosis in a patient.
11. The vessel of claim 10, wherein the carbon monoxide gas is in admixture with an  
5 oxygen-containing gas.
12. The vessel of claim 11, wherein the carbon monoxide gas is present in the admixture at a concentration of at least about 0.025%.
- 10 13. The vessel of claim 11, wherein the carbon monoxide gas is present in the admixture at a concentration of at least about 0.05%.
14. The vessel of claim 11, wherein the carbon monoxide gas is present in the admixture at a concentration of at least about 0.10%.
- 15 15. The vessel of claim 11, wherein the carbon monoxide gas is present in the admixture at a concentration of at least about 1.0%.
16. The vessel of claim 11, wherein the carbon monoxide gas is present in the  
20 admixture at a concentration of at least about 2.0%.
17. A vessel comprising medical grade compressed carbon monoxide gas, the vessel bearing a label indicating that the gas can be used to reduce arteriosclerosis in a patient.
- 25 18. The vessel of claim 17, wherein the carbon monoxide gas is present in the admixture at a concentration of at least about 0.025%.
19. The vessel of claim 17, wherein the carbon monoxide gas is present in the admixture at a concentration of at least about 0.05%.
- 30 20. The vessel of claim 17, wherein the carbon monoxide gas is present in the admixture at a concentration of at least about 0.10%.

21. The vessel of claim 17, wherein the carbon monoxide gas is present in the admixture at a concentration of at least about 1.0%.

22. The vessel of claim 17, wherein the carbon monoxide gas is present in the  
5 admixture at a concentration of at least about 2.0%.

23. A vessel comprising medical grade compressed carbon monoxide gas, the vessel bearing a label indicating that the gas can be used in conjunction with an angioplasty procedure in a patient.

10

24. The vessel of claim 23, wherein the carbon monoxide gas is present in the admixture at a concentration of at least about 0.025%.

25. The vessel of claim 23, wherein the carbon monoxide gas is present in the  
15 admixture at a concentration of at least about 0.05%.

26. The vessel of claim 23, wherein the carbon monoxide gas is present in the admixture at a concentration of at least about 0.10%.

20 27. The vessel of claim 23, wherein the carbon monoxide gas is present in the admixture at a concentration of at least about 1.0%.

28. The vessel of claim 23, wherein the carbon monoxide gas is present in the admixture at a concentration of at least about 2.0%.

25

29. A method of treating restenosis in a patient, comprising:

(a) identifying a patient suffering from or at risk for restenosis; and

(b) administering to the patient a pharmaceutical composition comprising an amount of carbon monoxide effective to treat restenosis in the patient.

30

30. The method of claim 29, wherein the restenosis results from balloon angioplasty.

31. The method of claim 29, wherein the restenosis results from laser angioplasty.

32. The method of claim 29, wherein the restenosis results from directional atherectomy.
33. The method of claim 29, wherein the restenosis results from rotational  
5 atherectomy.
34. The method of claim 29, wherein the restenosis results from extraction atherectomy.
- 10 35. The method of claim 29, wherein the restenosis results from a stenting procedure.
36. A method of treating intimal hyperplasia in a patient, comprising:  
    (a) identifying a patient suffering from or at risk for intimal hyperplasia not  
    resulting from a transplant procedure; and  
15      (b) administering to the patient a pharmaceutical composition comprising an  
    amount of carbon monoxide effective to treat intimal hyperplasia in the patient.
37. The method of claim 36, wherein the intimal hyperplasia results from balloon  
angioplasty.  
20
38. The method of claim 36, wherein the intimal hyperplasia results from laser  
angioplasty.
39. The method of claim 36, wherein the intimal hyperplasia results from directional  
25 atherectomy.
40. The method of claim 36, wherein the intimal hyperplasia results from rotational  
atherectomy.
- 30 41. The method of claim 36, wherein the intimal hyperplasia results from extraction  
atherectomy.
42. The method of claim 36, wherein the intimal hyperplasia results from a stenting  
procedure.



43. A method of performing angioplasty in a patient, comprising:

(a) providing an angioplasty device capable of administering carbon monoxide to a patient;

(b) positioning the device in a blood vessel in need of angioplasty;

5 (c) performing angioplasty using the device; and

(d) before, during or after (c), using the device to administer carbon monoxide to the blood vessel in an amount sufficient to treat intimal hyperplasia.

44. A kit comprising:

10 (a) an angioplasty device; and

(b) a vessel containing a carbon monoxide composition.

45. The kit of claim 44, wherein the angioplasty device is capable of administering carbon monoxide to a patient.

15

46. The kit of claim 44, further comprising:

(c) instructions for use of the carbon monoxide composition in a method for performing angioplasty in a patient.

20 47. The kit of claim 44, wherein the carbon monoxide composition is a liquid composition.



48. The kit of claim 44, wherein the carbon monoxide composition is a gaseous composition.

25




49. An angioplasty device comprising:

an inflatable member comprising a plurality of apertures; and



a reservoir comprising carbon monoxide gas and connected to the inflatable member, whereby the gas is provided to the inflatable member during inflation of the  
30 inflatable member.




**FIGS. 1A-1I**




FIGS. 2A-2C




FIGS. 3A-3G




FIGS. 4A-4F




FIGS. 5A-5G



**B**



FIGS. 6A-6B



FIGS. 7A-7B







FIG. 8



FIGS. 9A-9G






FIG. 10



FIGS. 11A-11B



FIGS. 12A-12C




FIG. 13A




FIG 13B




FIG. 13C




FIG. 13D



Figure 14a




Figure 14b





Figure 15





(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
4 September 2003 (04.09.2003)

PCT

(10) International Publication Number  
**WO 2003/072024 A3**

- (51) International Patent Classification<sup>7</sup>: **A61K 33/00**
- (21) International Application Number:  
PCT/US2003/004665
- (22) International Filing Date: 13 February 2003 (13.02.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/356,718 13 February 2002 (13.02.2002) US
- (71) Applicants (*for all designated States except US*): **BETH ISRAEL DEACONESS MEDICAL CENTER, INC.** [US/US]; One Deaconess Road, Boston, MA 02115 (US). **UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION** [US/US]; 200 Gardener Steel Conference Center, Pittsburgh, PA 15260 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **OTTERBEIN, Leo, E.** [US/US]; 910 Normandy Drive, New Kensington, PA 15068 (US). **CHOI, Augustine, M., K.** [US/US]; 43 Long Meadow Dr, Pittsburgh, PA 15238 (US). **BACH, Fritz, H.** [US/US]; 8 Blossom Lane, Manchester-by-the-Sea, MA 01944 (US). **ZUCKERBRAUN, Brian** [US/US]; 108 Maple Heights Road, Pittsburgh, PA 15232 (US).
- (74) Agent: **FRASER, Janis, K.**; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report
- (88) Date of publication of the international search report:  
26 February 2004
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHODS OF TREATING VASCULAR DISEASE

(57) Abstract: The present invention relates to a method of treating patients suffering from, or at risk for, intimal hyperplasia and/or arteriosclerosis. The treatment includes administering a pharmaceutical composition that includes carbon monoxide to the patient.



**WO 2003/072024 A3**

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/04665

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 33/00

US CL : 424/699

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/699

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,180,366 A (WOODS) 19 January 1993 (19.01.93), see the entire document.	1-49
A	US 5,449,665 A (SOLEVI) 12 September 1995 (12.09.95), see the entire document.	1-49

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

09 June 2003 (09.06.2003)

Date of mailing of the international search report

11 DEC 2003

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Facsimile No. (703)305-3230

Authorized officer

Raymond J. Henley Jr.

Telephone No. 703-308-1235